{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:14:38Z","timestamp":1789409678480,"version":"build-2803163510"},"reference-count":433,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Changsha Natural Science Foundation of Hunan Provincial of China","award":["kq2208376"],"award-info":[{"award-number":["kq2208376"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00760-w","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:35:55Z","timestamp":1770827755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Youwen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"16","key":"760_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029\u201330.","journal-title":"Cancer"},{"issue":"1","key":"760_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/138161210789941847","volume":"16","author":"A Urruticoechea","year":"2010","unstructured":"Urruticoechea A, Alemany R, Balart J, et al. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16(1):3\u201310.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"760_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","volume":"9","author":"R Baskar","year":"2012","unstructured":"Baskar R, Lee KA, Yeo R, et al. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193\u20139.","journal-title":"Int J Med Sci"},{"issue":"6","key":"760_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007362","volume":"14","author":"A Nebbioso","year":"2018","unstructured":"Nebbioso A, Tambaro FP, Dell\u2019Aversana C, et al. Cancer epigenetics: moving forward. PLoS Genet. 2018;14(6):e1007362.","journal-title":"PLoS Genet"},{"key":"760_CR5","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2021.4","volume":"23","author":"X Dai","year":"2021","unstructured":"Dai X, Ren T, Zhang Y, et al. Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 2021;23:e2.","journal-title":"Expert Rev Mol Med"},{"issue":"11","key":"760_CR6","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1021\/ja01688a030","volume":"47","author":"TB Johnson","year":"1925","unstructured":"Johnson TB, Coghill RD. Researches on pyrimidines. c111. The discovery of 5-methyl-cytosine in tuberculinic acid, the nucleic acid of the tubercle bacillus1. J Am Chem Soc. 1925;47(11):2838\u201344.","journal-title":"J Am Chem Soc"},{"issue":"10","key":"760_CR7","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6765","key":"760_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/47412","volume":"403","author":"BD Strahl","year":"2000","unstructured":"Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41\u20135.","journal-title":"Nature"},{"key":"760_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev.bi.52.070183.000521","volume":"52","author":"W Doerfler","year":"1983","unstructured":"Doerfler W. DNA methylation and gene activity. Annu Rev Biochem. 1983;52:93\u2013124.","journal-title":"Annu Rev Biochem"},{"key":"760_CR10","first-page":"1","volume":"40","author":"AD Riggs","year":"1983","unstructured":"Riggs AD, Jones PA. 5-methylcytosine, gene regulation, and cancer. Adv Cancer Res. 1983;40:1\u201330.","journal-title":"Adv Cancer Res"},{"issue":"10","key":"760_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/ncb1642","volume":"9","author":"N Cheung","year":"2007","unstructured":"Cheung N, Chan LC, Thompson A, et al. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol. 2007;9(10):1208\u201315.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"760_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nm.4416","volume":"23","author":"LP Vu","year":"2017","unstructured":"Vu LP, Pickering BF, Cheng Y, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369\u201376.","journal-title":"Nat Med"},{"key":"760_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2164-11-48","volume":"11","author":"YA Medvedeva","year":"2010","unstructured":"Medvedeva YA, Fridman MV, Oparina NJ, et al. Intergenic, gene terminal, and intragenic CpG islands in the human genome. BMC Genomics. 2010;11:48.","journal-title":"BMC Genomics"},{"key":"760_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-60","volume":"5","author":"M Ducasse","year":"2006","unstructured":"Ducasse M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer. 2006;5:60.","journal-title":"Mol Cancer"},{"issue":"2","key":"760_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/nbt.2487","volume":"31","author":"Y Liu","year":"2013","unstructured":"Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013;31(2):142\u20137.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"760_CR16","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.7150\/ijbs.87028","volume":"19","author":"M Kong","year":"2023","unstructured":"Kong M, Yu X, Guo W, et al. The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors. Int J Biol Sci. 2023;19(15):4834\u201348.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"760_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327.","journal-title":"Cell"},{"issue":"3","key":"760_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12519-016-0020-3","volume":"12","author":"P Xie","year":"2016","unstructured":"Xie P, Zang LQ, Li XK, et al. An epigenetic view of developmental diseases: new targets, new therapies. World J Pediatr. 2016;12(3):291\u20137.","journal-title":"World J Pediatr"},{"issue":"2","key":"760_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020195","volume":"11","author":"M Nikolac Perkovic","year":"2021","unstructured":"Nikolac Perkovic M, Videtic Paska A, Konjevod M, et al. Epigenetics of Alzheimer\u2019s disease. Biomolecules. 2021;11(2):195.","journal-title":"Biomolecules"},{"issue":"10","key":"760_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41580-019-0143-1","volume":"20","author":"EM Michalak","year":"2019","unstructured":"Michalak EM, Burr ML, Bannister AJ, et al. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 2019;20(10):573\u201389.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"760_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01726-x","volume":"18","author":"J Tang","year":"2025","unstructured":"Tang J, Zhuang Y, Zhang Y, et al. Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications. J Hematol Oncol. 2025;18(1):77.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"760_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/1947601910393957","volume":"2","author":"B Jin","year":"2011","unstructured":"Jin B, Li Y, Robertson KD. DNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer. 2011;2(6):607\u201317.","journal-title":"Genes Cancer"},{"issue":"1","key":"760_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","volume":"22","author":"JS You","year":"2012","unstructured":"You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22(1):9\u201320.","journal-title":"Cancer Cell"},{"issue":"7472","key":"760_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","volume":"502","author":"RM Kohli","year":"2013","unstructured":"Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502(7472):472\u20139.","journal-title":"Nature"},{"issue":"3","key":"760_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.stem.2011.08.007","volume":"9","author":"L Cimmino","year":"2011","unstructured":"Cimmino L, Abdel-Wahab O, Levine RL, et al. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell. 2011;9(3):193\u2013204.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"760_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2018.06.015","volume":"71","author":"CL Xiao","year":"2018","unstructured":"Xiao CL, Zhu S, He M, et al. N(6)-Methyladenine DNA Modification in the Human Genome. Mol Cell. 2018;71(2):306-18.e7.","journal-title":"Mol Cell"},{"issue":"10","key":"760_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","volume":"20","author":"MVC Greenberg","year":"2019","unstructured":"Greenberg MVC, Bourc\u2019his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20(10):590\u2013607.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"760_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","volume":"70","author":"M Kulis","year":"2010","unstructured":"Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27\u201356.","journal-title":"Adv Genet"},{"issue":"4","key":"760_CR29","first-page":"722","volume":"56","author":"JG Herman","year":"1996","unstructured":"Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56(4):722\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"760_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0719-9","volume":"11","author":"X Jiao","year":"2019","unstructured":"Jiao X, Zhang S, Jiao J, et al. Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance. Clin Epigenetics. 2019;11(1):120.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"760_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2023.2179916","volume":"43","author":"L He","year":"2023","unstructured":"He L, Luo X, Bu Q, et al. PAX1 and SEPT9 methylation analyses in cervical exfoliated cells are highly efficient for detecting cervical (pre)cancer in hrHPV-positive women. J Obstet Gynaecol. 2023;43(1):2179916.","journal-title":"J Obstet Gynaecol"},{"issue":"16","key":"760_CR32","first-page":"3347","volume":"57","author":"A Dobrovic","year":"1997","unstructured":"Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997;57(16):3347\u201350.","journal-title":"Cancer Res"},{"key":"760_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-1-72","volume":"1","author":"ML McCoy","year":"2003","unstructured":"McCoy ML, Mueller CR, Roskelley CD. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol. 2003;1:72.","journal-title":"Reprod Biol Endocrinol"},{"issue":"2","key":"760_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cancergencyto.2005.07.023","volume":"165","author":"FF Costa","year":"2006","unstructured":"Costa FF, Paix\u00e3o VA, Cavalher FP, et al. SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet. 2006;165(2):135\u201343.","journal-title":"Cancer Genet Cytogenet"},{"issue":"13","key":"760_CR35","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1158\/0008-5472.CAN-04-0238","volume":"64","author":"M Widschwendter","year":"2004","unstructured":"Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004;64(13):4472\u201380.","journal-title":"Cancer Res"},{"issue":"11","key":"760_CR36","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1158\/0008-5472.CAN-03-3852","volume":"64","author":"M Widschwendter","year":"2004","unstructured":"Widschwendter M, Siegmund KD, M\u00fcller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004;64(11):3807\u201313.","journal-title":"Cancer Res"},{"issue":"11","key":"760_CR37","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.1128\/JVI.77.11.6227-6234.2003","volume":"77","author":"V Badal","year":"2003","unstructured":"Badal V, Chuang LS, Tan EH, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol. 2003;77(11):6227\u201334.","journal-title":"J Virol"},{"issue":"3\u20134","key":"760_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.bbagrm.2009.10.005","volume":"1799","author":"M Takacs","year":"2010","unstructured":"Takacs M, Banati F, Koroknai A, et al. Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta. 2010;1799(3\u20134):228\u201335.","journal-title":"Biochim Biophys Acta"},{"issue":"35","key":"760_CR39","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.3748\/wjg.v12.i35.5651","volume":"12","author":"KH Kim","year":"2006","unstructured":"Kim KH, Choi JS, Kim IJ, et al. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J Gastroenterol. 2006;12(35):5651\u20137.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"760_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40164-025-00704-w","volume":"14","author":"SA Xie","year":"2025","unstructured":"Xie SA, Li X, Yin MY, et al. Extracellular matrix stiffness reduces DNA 6 ma level to facilitate colorectal cancer progression via disrupting P53 binding to CDKN1A promoter. Exp Hematol Oncol. 2025;14(1):111.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"760_CR41","first-page":"1766","volume":"54","author":"J Weber","year":"1994","unstructured":"Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2019-deoxycytidine. Cancer Res. 1994;54(7):1766\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"760_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13046-018-0977-y","volume":"37","author":"S Xu","year":"2018","unstructured":"Xu S, Yue Y, Zhang S, et al. STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1\/MUC1 pathway. J Exp Clin Cancer Res. 2018;37(1):305.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"760_CR43","first-page":"664","volume":"63","author":"A Gupta","year":"2003","unstructured":"Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003;63(3):664\u201373.","journal-title":"Cancer Res"},{"issue":"7","key":"760_CR44","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1158\/1078-0432.CCR-03-0107","volume":"10","author":"N Yanagawa","year":"2004","unstructured":"Yanagawa N, Tamura G, Honda T, et al. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res. 2004;10(7):2447\u201351.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"760_CR45","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1073\/pnas.95.12.6870","volume":"95","author":"JG Herman","year":"1998","unstructured":"Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95(12):6870\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"760_CR46","first-page":"591","volume":"58","author":"SK My\u00f6h\u00e4nen","year":"1998","unstructured":"My\u00f6h\u00e4nen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 1998;58(4):591\u20133.","journal-title":"Cancer Res"},{"issue":"6","key":"760_CR47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","volume":"20","author":"I Barbieri","year":"2020","unstructured":"Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303\u201322.","journal-title":"Nat Rev Cancer"},{"key":"760_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105937","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, Wang JQ, Tan Y, et al. RNA methylation and cancer treatment. Pharmacol Res. 2021;174:105937.","journal-title":"Pharmacol Res"},{"issue":"2","key":"760_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41416-023-02275-1","volume":"129","author":"Q Tang","year":"2023","unstructured":"Tang Q, Li L, Wang Y, et al. RNA modifications in cancer. Br J Cancer. 2023;129(2):204\u201321.","journal-title":"Br J Cancer"},{"issue":"1","key":"760_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-025-01665-7","volume":"18","author":"Q Wu","year":"2025","unstructured":"Wu Q, Fu X, Liu G, et al. N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential. J Hematol Oncol. 2025;18(1):12.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"760_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40164-025-00648-1","volume":"14","author":"YP Ding","year":"2025","unstructured":"Ding YP, Liu CC, Yu KD. RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond. Exp Hematol Oncol. 2025;14(1):48.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"760_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40164-024-00477-8","volume":"13","author":"P Zhao","year":"2024","unstructured":"Zhao P, Xia L, Chen D, et al. METTL1 mediated tRNA m(7)G modification promotes leukaemogenesis of AML via tRNA regulated translational control. Exp Hematol Oncol. 2024;13(1):8.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"760_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-022-00370-2","volume":"12","author":"W Wang","year":"2023","unstructured":"Wang W, Huang Q, Liao Z, et al. ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner. Exp Hematol Oncol. 2023;12(1):1.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"760_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-024-01599-6","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang J, Xiu M, Wang J, et al. METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma. J Hematol Oncol. 2024;17(1):78.","journal-title":"J Hematol Oncol"},{"key":"760_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, et al. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"760_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tig.2006.01.003","volume":"22","author":"VN Kim","year":"2006","unstructured":"Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22(3):165\u201373.","journal-title":"Trends Genet"},{"issue":"1","key":"760_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","volume":"302","author":"B Zhang","year":"2007","unstructured":"Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1\u201312.","journal-title":"Dev Biol"},{"issue":"11","key":"760_CR58","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"760_CR59","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","volume":"20","author":"J Hayes","year":"2014","unstructured":"Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460\u20139.","journal-title":"Trends Mol Med"},{"issue":"6","key":"760_CR60","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1109\/TCBB.2020.2993150","volume":"18","author":"H Yaghoobi","year":"2021","unstructured":"Yaghoobi H, Babaei E, Hussen BM, et al. EBST: an evolutionary multi-objective optimization based tool for discovering potential biomarkers in ovarian cancer. IEEE\/ACM Trans Comput Biol Bioinform. 2021;18(6):2384\u201393.","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"issue":"1","key":"760_CR61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/cells9010220","volume":"9","author":"I Conti","year":"2020","unstructured":"Conti I, Varano G, Simioni C, et al. miRNAs as influencers of cell-cell communication in tumor microenvironment. Cells. 2020;9(1):220.","journal-title":"Cells"},{"key":"760_CR62","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1038\/ncomms6812","volume":"5","author":"Y S\u00e1nchez","year":"2014","unstructured":"S\u00e1nchez Y, Segura V, Mar\u00edn-B\u00e9jar O, et al. Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun. 2014;5:5812.","journal-title":"Nat Commun"},{"issue":"3","key":"760_CR63","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","volume":"142","author":"M Huarte","year":"2010","unstructured":"Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409\u201319.","journal-title":"Cell"},{"issue":"24","key":"760_CR64","doi-asserted-by":"publisher","first-page":"12543","DOI":"10.18632\/oncotarget.3033","volume":"5","author":"JR Hart","year":"2014","unstructured":"Hart JR, Roberts TC, Weinberg MS, et al. MYC regulates the non-coding transcriptome. Oncotarget. 2014;5(24):12543\u201354.","journal-title":"Oncotarget"},{"issue":"4","key":"760_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju505","volume":"107","author":"T Kim","year":"2015","unstructured":"Kim T, Jeon YJ, Cui R, et al. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis. J Natl Cancer Inst. 2015;107(4):dju505.","journal-title":"J Natl Cancer Inst"},{"key":"760_CR66","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1038\/ncomms6383","volume":"5","author":"D Chakravarty","year":"2014","unstructured":"Chakravarty D, Sboner A, Nair SS, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014;5:5383.","journal-title":"Nat Commun"},{"issue":"3","key":"760_CR67","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cell.2014.05.049","volume":"158","author":"T Trimarchi","year":"2014","unstructured":"Trimarchi T, Bilal E, Ntziachristos P, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158(3):593\u2013606.","journal-title":"Cell"},{"issue":"6","key":"760_CR68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrd4018","volume":"12","author":"C Wahlestedt","year":"2013","unstructured":"Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12(6):433\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"760_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrg.2015.10","volume":"17","author":"JJ Quinn","year":"2016","unstructured":"Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47\u201362.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"760_CR70","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452\u201363.","journal-title":"Cancer Cell"},{"issue":"3","key":"760_CR71","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2018.06.014","volume":"174","author":"JT Hua","year":"2018","unstructured":"Hua JT, Ahmed M, Guo H, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell. 2018;174(3):564-75.e18.","journal-title":"Cell"},{"issue":"1","key":"760_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03229-y","volume":"43","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yan W, Jin H, et al. Transcriptional and post-transcriptional regulation of CARMN and its anti-tumor function in cervical cancer through autophagic flux blockade and MAPK cascade inhibition. J Exp Clin Cancer Res. 2024;43(1):305.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"760_CR73","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ng.3637","volume":"48","author":"H Guo","year":"2016","unstructured":"Guo H, Ahmed M, Zhang F, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016;48(10):1142\u201350.","journal-title":"Nat Genet"},{"issue":"1","key":"760_CR74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-020-00446-7","volume":"6","author":"T Yan","year":"2021","unstructured":"Yan T, Shen C, Jiang P, et al. Risk SNP-induced lncRNA-SLCC1 drives colorectal cancer through activating glycolysis signaling. Signal Transduct Target Ther. 2021;6(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"760_CR75","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/ng.3568","volume":"48","author":"J Zheng","year":"2016","unstructured":"Zheng J, Huang X, Tan W, et al. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat Genet. 2016;48(7):747\u201357.","journal-title":"Nat Genet"},{"issue":"10","key":"760_CR76","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"760_CR77","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3892\/ol.2020.11794","volume":"20","author":"L Jiang","year":"2020","unstructured":"Jiang L, Chen T, Xiong L, et al. Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation. Oncol Lett. 2020;20(3):2191\u20138.","journal-title":"Oncol Lett"},{"issue":"3","key":"760_CR78","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3892\/or.2020.7665","volume":"44","author":"J Xu","year":"2020","unstructured":"Xu J, Chen Q, Tian K, et al. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation. Oncol Rep. 2020;44(3):973\u201386.","journal-title":"Oncol Rep"},{"issue":"6","key":"760_CR79","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254\u201370.","journal-title":"Hepatology"},{"key":"760_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2017.11.018","volume":"415","author":"X Cai","year":"2018","unstructured":"Cai X, Wang X, Cao C, et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018;415:11\u20139.","journal-title":"Cancer Lett"},{"issue":"8","key":"760_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113165","volume":"28","author":"TH Lan","year":"2025","unstructured":"Lan TH, Li W, Wang X, et al. METTL3 promotes peritoneal metastasis of colorectal cancer through regulating m6A modification of NRXN3 mRNA. iScience. 2025;28(8):113165.","journal-title":"iScience"},{"issue":"16","key":"760_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt7682","volume":"11","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Zhang L, Xia L, et al. A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma. Sci Adv. 2025;11(16):eadt7682.","journal-title":"Sci Adv"},{"issue":"4","key":"760_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70022","volume":"16","author":"X Guo","year":"2025","unstructured":"Guo X, Huang A, Qi Y, et al. METTL3\/IGF2BP2 promotes the malignant progression of esophageal cancer by activating the PIK3CA\/AKT pathway. Thorac Cancer. 2025;16(4):e70022.","journal-title":"Thorac Cancer"},{"issue":"1","key":"760_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-24958-w","volume":"15","author":"X Lin","year":"2025","unstructured":"Lin X, Hong Y, You S, et al. METTL3-mediated m6A modification of LINC00857 enhances stemness and metastasis of ovarian cancer cells by activating the YAP-TEAD pathway. Sci Rep. 2025;15(1):41132.","journal-title":"Sci Rep"},{"issue":"1","key":"760_CR85","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43556-025-00256-9","volume":"6","author":"R Li","year":"2025","unstructured":"Li R, Li S, Shen L, et al. M6A-modified BFSP1 induces aerobic glycolysis to promote liver cancer growth and metastasis through upregulating tropomodulin 4. Mol Biomed. 2025;6(1):17.","journal-title":"Mol Biomed"},{"key":"760_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081758","author":"A Chellamuthu","year":"2020","unstructured":"Chellamuthu A, Gray SG. The RNA methyltransferase NSUN2 and its potential roles in cancer. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9081758.","journal-title":"Cells"},{"issue":"19","key":"760_CR87","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1128\/MCB.00243-14","volume":"34","author":"S Yuan","year":"2014","unstructured":"Yuan S, Tang H, Xing J, et al. Methylation by NSun2 represses the levels and function of microRNA 125b. Mol Cell Biol. 2014;34(19):3630\u201341.","journal-title":"Mol Cell Biol"},{"issue":"44","key":"760_CR88","doi-asserted-by":"publisher","first-page":"26627","DOI":"10.1074\/jbc.M115.667717","volume":"290","author":"L Yang","year":"2015","unstructured":"Yang L, Ma Y, Han W, et al. Proteinase-activated receptor 2 promotes cancer cell migration through RNA methylation-mediated repression of miR-125b. J Biol Chem. 2015;290(44):26627\u201337.","journal-title":"J Biol Chem"},{"issue":"1","key":"760_CR89","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41698-025-00904-x","volume":"9","author":"Z Wang","year":"2025","unstructured":"Wang Z, Mierxiati A, Zhu W, et al. FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner. NPJ Precis Oncol. 2025;9(1):127.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"760_CR90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41419-025-07414-5","volume":"16","author":"Q Qi","year":"2025","unstructured":"Qi Q, Zhong R, Huang Y, et al. The RNA M5C methyltransferase NSUN2 promotes progression of hepatocellular carcinoma by enhancing PKM2-mediated glycolysis. Cell Death Dis. 2025;16(1):82.","journal-title":"Cell Death Dis"},{"key":"760_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217939","volume":"631","author":"M Zhang","year":"2025","unstructured":"Zhang M, Tang C, Li S, et al. NSUN2-mediated m(5)C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis. Cancer Lett. 2025;631:217939.","journal-title":"Cancer Lett"},{"issue":"1","key":"760_CR92","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13046-025-03483-8","volume":"44","author":"S Huang","year":"2025","unstructured":"Huang S, Liu Y, Zhao M, et al. Copy number amplification of TTPAL promotes cholesterol biosynthesis and esophageal squamous cell carcinoma progression via elevating NSUN2-mediated m5C modification of SREBP2 mRNA. J Exp Clin Cancer Res. 2025;44(1):220.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13-16","key":"760_CR93","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/15384101.2025.2544829","volume":"24","author":"S Liu","year":"2025","unstructured":"Liu S, Xu B, Zhao J. NSUN2-mediated m5C modification of PGK1 mRNA promotes cell growth, invasion, stemness and glycolysis in gastric cancer. Cell Cycle. 2025;24(13\u201316):283\u201395.","journal-title":"Cell Cycle"},{"issue":"1","key":"760_CR94","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1038\/s41467-021-26718-6","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang J, Li X, et al. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12(1):6314.","journal-title":"Nat Commun"},{"issue":"10","key":"760_CR95","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1089\/dna.2020.5624","volume":"39","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang Q, Huang Y, et al. m(1)A Regulator TRMT10C Predicts Poorer Survival and Contributes to Malignant Behavior in Gynecological Cancers. DNA Cell Biol. 2020;39(10):1767\u201378.","journal-title":"DNA Cell Biol"},{"key":"760_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143397","author":"L Jiang","year":"2022","unstructured":"Jiang L, Hao Y, Shao C, et al. ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI143397.","journal-title":"J Clin Invest"},{"issue":"10","key":"760_CR97","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1074\/jbc.M117.779868","volume":"292","author":"E Oakes","year":"2017","unstructured":"Oakes E, Anderson A, Cohen-Gadol A, et al. Adenosine Deaminase that acts on RNA 3 (ADAR3) binding to glutamate receptor subunit B Pre-mRNA inhibits RNA editing in glioblastoma. J Biol Chem. 2017;292(10):4326\u201335.","journal-title":"J Biol Chem"},{"issue":"4","key":"760_CR98","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/nar\/gkx1257","volume":"46","author":"V Cesarini","year":"2018","unstructured":"Cesarini V, Silvestris DA, Tassinari V, et al. ADAR2\/miR-589-3p axis controls glioblastoma cell migration\/invasion. Nucleic Acids Res. 2018;46(4):2045\u201359.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"760_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0279-9","volume":"9","author":"Y Song","year":"2016","unstructured":"Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol. 2016;9(1):49.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"760_CR100","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-023-03074-7","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Tang H, Hu N, et al. Methylomics and cancer: the current state of methylation profiling and marker development for clinical care. Cancer Cell Int. 2023;23(1):242.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"760_CR101","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/0955-0674(93)90080-A","volume":"5","author":"S Clarke","year":"1993","unstructured":"Clarke S. Protein methylation. Curr Opin Cell Biol. 1993;5(6):977\u201383.","journal-title":"Curr Opin Cell Biol"},{"key":"760_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-8104-5_1","volume":"1283","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Sun Z, Jia J, et al. Overview of histone modification. Adv Exp Med Biol. 2021;1283:1\u201316.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"760_CR103","first-page":"868","volume":"41","author":"J Ma","year":"2018","unstructured":"Ma J, Zhang J, Weng YC, et al. EZH2-Mediated microRNA-139-5p regulates epithelial-mesenchymal transition and lymph node metastasis of pancreatic cancer. Mol Cells. 2018;41(9):868\u201380.","journal-title":"Mol Cells"},{"issue":"6","key":"760_CR104","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2017.01.043","volume":"152","author":"NM Chen","year":"2017","unstructured":"Chen NM, Neesse A, Dyck ML, et al. Context-dependent epigenetic regulation of nuclear factor of activated T cells 1 in pancreatic plasticity. Gastroenterology. 2017;152(6):1507-20.e15.","journal-title":"Gastroenterology"},{"issue":"1","key":"760_CR105","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-020-00252-1","volume":"5","author":"Y Chen","year":"2020","unstructured":"Chen Y, Ren B, Yang J, et al. The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduct Target Ther. 2020;5(1):143.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"760_CR106","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41419-019-1595-0","volume":"10","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Lu Q, Li C, et al. PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation. Cell Death Dis. 2019;10(5):359.","journal-title":"Cell Death Dis"},{"key":"760_CR107","doi-asserted-by":"publisher","first-page":"18709","DOI":"10.1038\/srep18709","volume":"5","author":"MR Pan","year":"2015","unstructured":"Pan MR, Hsu MC, Chen LT, et al. G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation. Sci Rep. 2015;5:18709.","journal-title":"Sci Rep"},{"issue":"6","key":"760_CR108","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S1097-2765(03)00479-9","volume":"12","author":"JC Rice","year":"2003","unstructured":"Rice JC, Briggs SD, Ueberheide B, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell. 2003;12(6):1591\u20138.","journal-title":"Mol Cell"},{"issue":"2","key":"760_CR109","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","volume":"6","author":"NL Henry","year":"2012","unstructured":"Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140\u20136.","journal-title":"Mol Oncol"},{"issue":"1","key":"760_CR110","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-025-01747-6","volume":"18","author":"D Guo","year":"2025","unstructured":"Guo D, Huang A, Sun J, et al. The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort study. J Hematol Oncol. 2025;18(1):94.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"760_CR111","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"760_CR112","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-1804-1_1","volume":"1238","author":"R Kanwal","year":"2015","unstructured":"Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. Methods Mol Biol. 2015;1238:3\u201325.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"760_CR113","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1158\/1940-6207.CAPR-08-0029","volume":"1","author":"JP Issa","year":"2008","unstructured":"Issa JP. Cancer prevention: epigenetics steps up to the plate. Cancer Prev Res (Phila). 2008;1(4):219\u201322.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"28","key":"760_CR114","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.1703577114","volume":"114","author":"X Hao","year":"2017","unstructured":"Hao X, Luo H, Krawczyk M, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci U S A. 2017;114(28):7414\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"760_CR115","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466\u201377.","journal-title":"Ann Oncol"},{"key":"760_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.781820","volume":"12","author":"JC Yang","year":"2022","unstructured":"Yang JC, Hu JJ, Li YX, et al. Clinical applications of liquid biopsy in hepatocellular carcinoma. Front Oncol. 2022;12:781820.","journal-title":"Front Oncol"},{"issue":"6","key":"760_CR117","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/cr.2014.44","volume":"24","author":"BK Thakur","year":"2014","unstructured":"Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24(6):766\u20139.","journal-title":"Cell Res"},{"key":"760_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010281","author":"HJ Cho","year":"2020","unstructured":"Cho HJ, Eun JW, Baek GO, et al. Serum exosomal microRNA, miR-10b-5p, as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9010281.","journal-title":"J Clin Med"},{"issue":"6","key":"760_CR119","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ijc.31931","volume":"144","author":"YR Lee","year":"2019","unstructured":"Lee YR, Kim G, Tak WY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer. 2019;144(6):1444\u201352.","journal-title":"Int J Cancer"},{"issue":"10","key":"760_CR120","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas M, Todenh\u00f6fer T, Black PC. Urine biomarkers in bladder cancer - current status and future perspectives. Nat Rev Urol. 2023;20(10):597\u2013614.","journal-title":"Nat Rev Urol"},{"key":"760_CR121","unstructured":"The National Medical Products Administration (NMPA). https:\/\/www.nmpa.gov.cn. Accessed March 2024."},{"issue":"4","key":"760_CR122","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","volume":"1","author":"JA Witjes","year":"2018","unstructured":"Witjes JA, Morote J, Cornel EB, et al. Performance of the bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective blinded clinical trial. Eur Urol Oncol. 2018;1(4):307\u201313.","journal-title":"Eur Urol Oncol"},{"issue":"3 Pt 1","key":"760_CR123","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.juro.2016.09.118","volume":"197","author":"KE van Kessel","year":"2017","unstructured":"van Kessel KE, Beukers W, Lurkin I, et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urol. 2017;197(3 Pt 1):590\u20135.","journal-title":"J Urol"},{"issue":"4","key":"760_CR124","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/IGC.0b013e3181c7fe6e","volume":"20","author":"TH Huang","year":"2010","unstructured":"Huang TH, Lai HC, Liu HW, et al. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer. 2010;20(4):513\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"760_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.457","volume":"11","author":"S Dong","year":"2021","unstructured":"Dong S, Lu Q, Xu P, et al. Hypermethylated PCDHGB7 as a universal cancer only marker and its application in early cervical cancer screening. Clin Transl Med. 2021;11(6):e457.","journal-title":"Clin Transl Med"},{"key":"760_CR126","doi-asserted-by":"publisher","DOI":"10.25259\/Cytojournal_46_2022","volume":"20","author":"Y Wen","year":"2023","unstructured":"Wen Y, Liang H, Zhang H. Clinical utility of HPV typing and quantification combined with PAX1\/ZNF582 methylation detection in accurate cervical cancer screening. Cytojournal. 2023;20:26.","journal-title":"Cytojournal"},{"issue":"20","key":"760_CR127","first-page":"1852","volume":"104","author":"X Shang","year":"2024","unstructured":"Shang X, Kong LH, Xiao XP, et al. A multicenter study on the accuracy of PAX1\/JAM3 dual genes methylation testing for screening cervical cancer. Zhonghua Yi Xue Za Zhi. 2024;104(20):1852\u20139.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"760_CR128","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ygyno.2016.02.012","volume":"141","author":"LMA De Strooper","year":"2016","unstructured":"De Strooper LMA, Verhoef VMJ, Berkhof J, et al. Validation of the FAM19A4\/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol. 2016;141(2):341\u20137.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"760_CR129","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ijc.30534","volume":"140","author":"A Kocsis","year":"2017","unstructured":"Kocsis A, Tak\u00e1cs T, Jeney C, et al. Performance of a new HPV and biomarker assay in the management of hrHPV positive women: subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. Int J Cancer. 2017;140(5):1119\u201333.","journal-title":"Int J Cancer"},{"key":"760_CR130","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/CMAR.S417877","volume":"15","author":"C Fan","year":"2023","unstructured":"Fan C, Ma Q, Wu X, et al. Detection of DNA methylation in gene loci ASTN1, DLX1, ITGA4, RXFP3, SOX17, and ZNF671 for diagnosis of cervical cancer. Cancer Manag Res. 2023;15:635\u201344.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"760_CR131","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13148-019-0642-0","volume":"11","author":"YD Han","year":"2019","unstructured":"Han YD, Oh TJ, Chung TH, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 2019;11(1):51.","journal-title":"Clin Epigenetics"},{"key":"760_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.706754","volume":"8","author":"L Zhang","year":"2021","unstructured":"Zhang L, Dong L, Lu C, et al. Methylation of SDC2\/TFPI2 and its diagnostic value in colorectal tumorous lesions. Front Mol Biosci. 2021;8:706754.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"760_CR133","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00384-022-04170-2","volume":"37","author":"J Lin","year":"2022","unstructured":"Lin J, Zhang L, Chen M, et al. Evaluation of combined detection of multigene mutation and SDC2\/SFRP2 methylation in stool specimens for colorectal cancer early diagnosis. Int J Colorectal Dis. 2022;37(6):1231\u20138.","journal-title":"Int J Colorectal Dis"},{"issue":"12","key":"760_CR134","doi-asserted-by":"publisher","first-page":"10241","DOI":"10.1007\/s00432-023-04943-4","volume":"149","author":"B Li","year":"2023","unstructured":"Li B, Liu S, Gao Y, et al. Combined detection of SDC2\/ADHFE1\/PPP2R5C methylation in stool DNA for colorectal cancer screening. J Cancer Res Clin Oncol. 2023;149(12):10241\u201353.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"760_CR135","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/gutjnl-2012-304149","volume":"63","author":"TR Church","year":"2014","unstructured":"Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317\u201325.","journal-title":"Gut"},{"issue":"8","key":"760_CR136","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000386","volume":"12","author":"F Xu","year":"2021","unstructured":"Xu F, Yu S, Han J, et al. Detection of circulating tumor DNA methylation in diagnosis of colorectal cancer. Clin Transl Gastroenterol. 2021;12(8):e00386.","journal-title":"Clin Transl Gastroenterol"},{"issue":"36","key":"760_CR137","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034955","volume":"102","author":"H Lu","year":"2023","unstructured":"Lu H, Lin D. Diagnostic value of exfoliated tumor cells combined with DNA methylation in bronchoalveolar lavage fluid for lung cancer. Medicine (Baltimore). 2023;102(36):e34955.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"760_CR138","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtho.2016.08.123","volume":"12","author":"G Weiss","year":"2017","unstructured":"Weiss G, Schlegel A, Kottwitz D, et al. Validation of the SHOX2\/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol. 2017;12(1):77\u201384.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"760_CR139","doi-asserted-by":"publisher","first-page":"16782","DOI":"10.1038\/s41598-021-96242-6","volume":"11","author":"B Wei","year":"2021","unstructured":"Wei B, Wu F, Xing W, et al. A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer. Sci Rep. 2021;11(1):16782.","journal-title":"Sci Rep"},{"key":"760_CR140","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02682-2020","author":"M Gaga","year":"2021","unstructured":"Gaga M, Chorostowska-Wynimko J, Horv\u00e1th I, et al. Validation of lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.02682-2020.","journal-title":"Eur Respir J"},{"issue":"11","key":"760_CR141","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/cac2.12478","volume":"43","author":"Y Nie","year":"2023","unstructured":"Nie Y, Gao X, Cai X, et al. Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer. Cancer Commun. 2023;43(11):1275\u20139.","journal-title":"Cancer Commun"},{"key":"760_CR142","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/IJGM.S395951","volume":"16","author":"J Guo","year":"2023","unstructured":"Guo J, Li J, Chang J, et al. Value of methylation status of RPRM, SDC2, and TCF4 genes in plasma for gastric adenocarcinoma screening. Int J Gen Med. 2023;16:673\u201381.","journal-title":"Int J Gen Med"},{"key":"760_CR143","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ebiom.2018.03.029","volume":"30","author":"A Oussalah","year":"2018","unstructured":"Oussalah A, Rischer S, Bensenane M, et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine. 2018;30:138\u201347.","journal-title":"EBioMedicine"},{"key":"760_CR144","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.urology.2018.04.001","volume":"128","author":"RL Waterhouse Jr","year":"2019","unstructured":"Waterhouse RL Jr, Van Neste L, Moses KA, et al. Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American Men. Urology. 2019;128:62\u20135.","journal-title":"Urology"},{"key":"760_CR145","first-page":"PO.18.00134","volume":"2019","author":"E O'Reilly","year":"2019","unstructured":"O\u2019Reilly E, Tuzova AV, Walsh AL, et al. epiCaPture: a urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol. 2019;2019:PO.18.00134.","journal-title":"JCO Precis Oncol"},{"key":"760_CR146","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oraloncology.2016.09.007","volume":"62","author":"SJ Cheng","year":"2016","unstructured":"Cheng SJ, Chang CF, Lee JJ, et al. Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer. Oral Oncol. 2016;62:34\u201343.","journal-title":"Oral Oncol"},{"key":"760_CR147","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.semcancer.2020.12.006","volume":"83","author":"P Mondal","year":"2022","unstructured":"Mondal P, Natesh J, Penta D, et al. Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: a clinical update. Semin Cancer Biol. 2022;83:503\u201322.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"760_CR148","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/03602532.2014.995379","volume":"47","author":"L Pleyer","year":"2015","unstructured":"Pleyer L, Greil R. Digging deep into \u201cdirty\u201d drugs - modulation of the methylation machinery. Drug Metab Rev. 2015;47(2):252\u201379.","journal-title":"Drug Metab Rev"},{"issue":"35","key":"760_CR149","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","volume":"21","author":"JK Christman","year":"2002","unstructured":"Christman JK. 5-azacytidine and 5-aza-2\u2019-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483\u201395.","journal-title":"Oncogene"},{"key":"760_CR150","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-3-642-54490-3_18","volume":"201","author":"B Hackanson","year":"2014","unstructured":"Hackanson B, Daskalakis M. Decitabine. Recent Results Cancer Res. 2014;201:269\u201397.","journal-title":"Recent Results Cancer Res"},{"issue":"8","key":"760_CR151","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","volume":"38","author":"EA Griffiths","year":"2013","unstructured":"Griffiths EA, Choy G, Redkar S, et al. SGI-110: DNA methyltransferase inhibitor oncolytic. Drugs Future. 2013;38(8):535\u201343.","journal-title":"Drugs Future"},{"issue":"10","key":"760_CR152","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/13543784.2019.1667331","volume":"28","author":"GS Daher-Reyes","year":"2019","unstructured":"Daher-Reyes GS, Merchan BM, Yee KWL. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Expert Opin Investig Drugs. 2019;28(10):835\u201349.","journal-title":"Expert Opin Investig Drugs"},{"issue":"17","key":"760_CR153","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1182\/bloodadvances.2023010179","volume":"7","author":"P Fenaux","year":"2023","unstructured":"Fenaux P, Gobbi M, Kropf PL, et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023;7(17):5027\u201337.","journal-title":"Blood Adv"},{"issue":"9","key":"760_CR154","first-page":"4831","volume":"46","author":"CJ van Groeningen","year":"1986","unstructured":"van Groeningen CJ, Leyva A, O\u2019Brien AM, et al. Phase I and pharmacokinetic study of 5-aza-2\u2019-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46(9):4831\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"760_CR155","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"5","key":"760_CR156","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/PPO.0000000000000283","volume":"23","author":"MT McCabe","year":"2017","unstructured":"McCabe MT, Mohammad HP, Barbash O, et al. Targeting histone methylation in cancer. Cancer J. 2017;23(5):292\u2013301.","journal-title":"Cancer J"},{"issue":"1","key":"760_CR157","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-023-00405-2","volume":"12","author":"B Wang","year":"2023","unstructured":"Wang B, Liu Y, Liao Z, et al. EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies. Exp Hematol Oncol. 2023;12(1):52.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"760_CR158","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128\u201334.","journal-title":"Nat Med"},{"issue":"6","key":"760_CR159","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tibs.2010.02.009","volume":"35","author":"L Morey","year":"2010","unstructured":"Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci. 2010;35(6):323\u201332.","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"760_CR160","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/med.21358","volume":"35","author":"W Wang","year":"2015","unstructured":"Wang W, Qin JJ, Voruganti S, et al. Polycomb Group (PcG) proteins and human cancers: multifaceted functions and therapeutic implications. Med Res Rev. 2015;35(6):1220\u201367.","journal-title":"Med Res Rev"},{"issue":"10","key":"760_CR161","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nsmb.2669","volume":"20","author":"L Di Croce","year":"2013","unstructured":"Di Croce L, Helin K. Transcriptional regulation by polycomb group proteins. Nat Struct Mol Biol. 2013;20(10):1147\u201355.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"760_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jb\/mvab007","volume":"170","author":"S Hanaki","year":"2021","unstructured":"Hanaki S, Shimada M. Targeting EZH2 as cancer therapy. J Biochem. 2021;170(1):1\u20134.","journal-title":"J Biochem"},{"issue":"7","key":"760_CR163","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ng.154","volume":"40","author":"Z Wang","year":"2008","unstructured":"Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40(7):897\u2013903.","journal-title":"Nat Genet"},{"issue":"7330","key":"760_CR164","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343\u20139.","journal-title":"Nature"},{"issue":"13","key":"760_CR165","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1128\/MCB.21.13.4330-4336.2001","volume":"21","author":"D O'Carroll","year":"2001","unstructured":"O\u2019Carroll D, Erhardt S, Pagani M, et al. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol. 2001;21(13):4330\u20136.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"760_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00600-3","volume":"14","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Luo Y, Ye L, et al. EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes. Exp Hematol Oncol. 2025;14(1):9.","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"760_CR167","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.jmb.2016.10.012","volume":"429","author":"M Wassef","year":"2017","unstructured":"Wassef M, Margueron R. The multiple facets of PRC2 alterations in cancers. J Mol Biol. 2017;429(13):1978\u201393.","journal-title":"J Mol Biol"},{"issue":"8","key":"760_CR168","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1515\/hsz-2019-0436","volume":"401","author":"SL Nutt","year":"2020","unstructured":"Nutt SL, Keenan C, Chopin M, et al. EZH2 function in immune cell development. Biol Chem. 2020;401(8):933\u201343.","journal-title":"Biol Chem"},{"issue":"13","key":"760_CR169","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1016\/j.celrep.2018.03.002","volume":"22","author":"T Ito","year":"2018","unstructured":"Ito T, Teo YV, Evans SA, et al. Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways. Cell Rep. 2018;22(13):3480\u201392.","journal-title":"Cell Rep"},{"key":"760_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"issue":"4","key":"760_CR171","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41556-021-00653-6","volume":"23","author":"Y Yi","year":"2021","unstructured":"Yi Y, Li Y, Meng Q, et al. A PRC2-independent function for EZH2 in regulating rRNA 2\u2019-O methylation and IRES-dependent translation. Nat Cell Biol. 2021;23(4):341\u201354.","journal-title":"Nat Cell Biol"},{"key":"760_CR172","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pharmthera.2016.05.003","volume":"165","author":"A Italiano","year":"2016","unstructured":"Italiano A. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacol Ther. 2016;165:26\u201331.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"760_CR173","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.stem.2019.03.005","volume":"24","author":"M Brand","year":"2019","unstructured":"Brand M, Nakka K, Zhu J, et al. Polycomb\/Trithorax antagonism: cellular memory in stem cell fate and function. Cell Stem Cell. 2019;24(4):518\u201333.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"760_CR174","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","volume":"17","author":"BA Jones","year":"2018","unstructured":"Jones BA, Varambally S, Arend RC. Histone methyltransferase EZH2: a therapeutic target for ovarian cancer. Mol Cancer Ther. 2018;17(3):591\u2013602.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"760_CR175","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","volume":"18","author":"BG Wilson","year":"2010","unstructured":"Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316\u201328.","journal-title":"Cancer Cell"},{"issue":"5","key":"760_CR176","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","volume":"191","author":"T Anwar","year":"2021","unstructured":"Anwar T, Gonzalez ME, Kleer CG. Noncanonical functions of the polycomb group protein EZH2 in breast cancer. Am J Pathol. 2021;191(5):774\u201383.","journal-title":"Am J Pathol"},{"issue":"2","key":"760_CR177","first-page":"193","volume":"1","author":"FM Pozo","year":"2022","unstructured":"Pozo FM, Hunter T, Zhang Y. The \u201cnew (Nu)-clear\u201d evidence for the tumor-driving role of PI3K. Acta Mater Med. 2022;1(2):193\u20136.","journal-title":"Acta Mater Med"},{"issue":"2","key":"760_CR178","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1747-0285.2011.01135.x","volume":"78","author":"VM Richon","year":"2011","unstructured":"Richon VM, Johnston D, Sneeringer CJ, et al. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des. 2011;78(2):199\u2013210.","journal-title":"Chem Biol Drug Des"},{"issue":"11","key":"760_CR179","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423\u201332.","journal-title":"Lancet Oncol"},{"issue":"11","key":"760_CR180","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"7265","key":"760_CR181","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature08398","volume":"461","author":"R Margueron","year":"2009","unstructured":"Margueron R, Justin N, Ohno K, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature. 2009;461(7265):762\u20137.","journal-title":"Nature"},{"key":"760_CR182","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/ncomms4127","volume":"5","author":"Q Cao","year":"2014","unstructured":"Cao Q, Wang X, Zhao M, et al. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014;5:3127.","journal-title":"Nat Commun"},{"issue":"4","key":"760_CR183","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nchembio.2304","volume":"13","author":"W Qi","year":"2017","unstructured":"Qi W, Zhao K, Gu J, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol. 2017;13(4):381\u20138.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"760_CR184","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.chembiol.2019.11.006","volume":"27","author":"F Potjewyd","year":"2020","unstructured":"Potjewyd F, Turner AW, Beri J, et al. Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader. Cell Chem Biol. 2020;27(1):47-56.e15.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"760_CR185","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","volume":"27","author":"JH Hsu","year":"2020","unstructured":"Hsu JH, Rasmusson T, Robinson J, et al. EED-Targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex. Cell Chem Biol. 2020;27(1):41-6.e17.","journal-title":"Cell Chem Biol"},{"issue":"27","key":"760_CR186","doi-asserted-by":"publisher","first-page":"16723","DOI":"10.1074\/jbc.M115.659433","volume":"290","author":"A Hadjikyriacou","year":"2015","unstructured":"Hadjikyriacou A, Yang Y, Espejo A, et al. Unique features of human protein arginine methyltransferase 9 (PRMT9) and its substrate RNA splicing factor SF3B2. J Biol Chem. 2015;290(27):16723\u201343.","journal-title":"J Biol Chem"},{"issue":"1","key":"760_CR187","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","volume":"36","author":"A Fedoriw","year":"2019","unstructured":"Fedoriw A, Rajapurkar SR, O\u2019Brien S, et al. Anti-tumor activity of the Type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 2019;36(1):100-14.e25.","journal-title":"Cancer Cell"},{"issue":"44","key":"760_CR188","doi-asserted-by":"publisher","first-page":"17960","DOI":"10.1073\/pnas.1209814109","volume":"109","author":"S Antonysamy","year":"2012","unstructured":"Antonysamy S, Bonday Z, Campbell RM, et al. Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci U S A. 2012;109(44):17960\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"760_CR189","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.2057811","volume":"25","author":"AT Nguyen","year":"2011","unstructured":"Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011;25(13):1345\u201358.","journal-title":"Genes Dev"},{"issue":"8","key":"760_CR190","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1158\/1535-7163.MCT-16-0693","volume":"16","author":"CT Campbell","year":"2017","unstructured":"Campbell CT, Haladyna JN, Drubin DA, et al. Mechanisms of pinometostat (EPZ-5676) treatment-emergent resistance in MLL-rearranged leukemia. Mol Cancer Ther. 2017;16(8):1669\u201379.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"760_CR191","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40164-023-00445-8","volume":"12","author":"P Schneider","year":"2023","unstructured":"Schneider P, Crump NT, Arentsen-Peters S, et al. Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia. Exp Hematol Oncol. 2023;12(1):81.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"760_CR192","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","volume":"122","author":"SR Daigle","year":"2013","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017\u201325.","journal-title":"Blood"},{"key":"760_CR193","doi-asserted-by":"publisher","first-page":"1120911","DOI":"10.3389\/fphar.2023.1120911","volume":"14","author":"B Noce","year":"2023","unstructured":"Noce B, Di Bello E, Fioravanti R, et al. LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials. Front Pharmacol. 2023;14:1120911.","journal-title":"Front Pharmacol"},{"issue":"6","key":"760_CR194","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1947601911417976","volume":"2","author":"D Rotili","year":"2011","unstructured":"Rotili D, Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer. 2011;2(6):663\u201379.","journal-title":"Genes Cancer"},{"issue":"1","key":"760_CR195","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1021\/jm4012802","volume":"57","author":"D Rotili","year":"2014","unstructured":"Rotili D, Tomassi S, Conte M, et al. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem. 2014;57(1):42\u201355.","journal-title":"J Med Chem"},{"issue":"5855","key":"760_CR196","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1126\/science.1151710","volume":"318","author":"T Gerken","year":"2007","unstructured":"Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5855):1469\u201372.","journal-title":"Science"},{"issue":"23-24","key":"760_CR197","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1016\/j.febslet.2008.08.019","volume":"582","author":"G Jia","year":"2008","unstructured":"Jia G, Yang CG, Yang S, et al. Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. FEBS Lett. 2008;582(23\u201324):3313\u20139.","journal-title":"FEBS Lett"},{"issue":"36","key":"760_CR198","doi-asserted-by":"publisher","first-page":"25046","DOI":"10.1074\/jbc.M803776200","volume":"283","author":"MP Westbye","year":"2008","unstructured":"Westbye MP, Feyzi E, Aas PA, et al. Human AlkB homolog 1 is a mitochondrial protein that demethylates 3-methylcytosine in DNA and RNA. J Biol Chem. 2008;283(36):25046\u201356.","journal-title":"J Biol Chem"},{"issue":"6925","key":"760_CR199","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nature01363","volume":"421","author":"PA Aas","year":"2003","unstructured":"Aas PA, Otterlei M, Falnes PO, et al. Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA. Nature. 2003;421(6925):859\u201363.","journal-title":"Nature"},{"issue":"1","key":"760_CR200","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","volume":"38","author":"R Su","year":"2020","unstructured":"Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38(1):79-96.e11.","journal-title":"Cancer Cell"},{"issue":"3","key":"760_CR201","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/BF00175300","volume":"5","author":"DS Alberts","year":"1987","unstructured":"Alberts DS, Mason-Liddil N, Green SJ, et al. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study. Invest New Drugs. 1987;5(3):289\u201392.","journal-title":"Invest New Drugs"},{"issue":"4","key":"760_CR202","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00170764","volume":"3","author":"TP Miller","year":"1985","unstructured":"Miller TP, Ahmann FR, Mackel C, et al. Phase II trial of bisantrene in non-small cell lung cancer. Invest New Drugs. 1985;3(4):393\u20135.","journal-title":"Invest New Drugs"},{"issue":"3","key":"760_CR203","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/BF00269035","volume":"13","author":"AA Forastiere","year":"1984","unstructured":"Forastiere AA, Perry MC, Hughes AK, et al. Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer. A cancer and leukemia group B study. Cancer Chemother Pharmacol. 1984;13(3):226\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"760_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05977-0","volume":"23","author":"T Zeyen","year":"2022","unstructured":"Zeyen T, Potthoff AL, Nemeth R, et al. Phase I\/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth\/NOA-24 trial. Trials. 2022;23(1):57.","journal-title":"Trials"},{"issue":"1","key":"760_CR205","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng C, Huang W, Li Y, et al. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13(1):117.","journal-title":"J Hematol Oncol"},{"issue":"7608","key":"760_CR206","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534(7608):575\u20138.","journal-title":"Nature"},{"issue":"2","key":"760_CR207","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63(2):306\u201317.","journal-title":"Mol Cell"},{"issue":"7748","key":"760_CR208","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41586-019-1016-7","volume":"567","author":"H Huang","year":"2019","unstructured":"Huang H, Weng H, Zhou K, et al. Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally. Nature. 2019;567(7748):414\u20139.","journal-title":"Nature"},{"issue":"6","key":"760_CR209","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jpha.2023.04.009","volume":"13","author":"H Xiao","year":"2023","unstructured":"Xiao H, Zhao R, Meng W, et al. Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer. J Pharm Anal. 2023;13(6):625\u201339.","journal-title":"J Pharm Anal"},{"issue":"4","key":"760_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115484","volume":"44","author":"Q Xia","year":"2025","unstructured":"Xia Q, Zhong R, Zheng J, et al. PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms. Cell Rep. 2025;44(4):115484.","journal-title":"Cell Rep"},{"issue":"4","key":"760_CR211","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011108","volume":"13","author":"Y Tong","year":"2025","unstructured":"Tong Y, Chen Z, Wu J, et al. METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5\/CCL5 regulation. J Immunother Cancer. 2025;13(4):e011108.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"760_CR212","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41419-025-07560-w","volume":"16","author":"CQ Jiao","year":"2025","unstructured":"Jiao CQ, Hu C, Sun MH, et al. Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia. Cell Death Dis. 2025;16(1):233.","journal-title":"Cell Death Dis"},{"issue":"3","key":"760_CR213","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12032-025-02634-3","volume":"42","author":"C Gao","year":"2025","unstructured":"Gao C, Yang H, Cheng J, et al. STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis. Med Oncol. 2025;42(3):82.","journal-title":"Med Oncol"},{"issue":"4","key":"760_CR214","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/epi.11.71","volume":"3","author":"TM Hardy","year":"2011","unstructured":"Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenomics. 2011;3(4):503\u201318.","journal-title":"Epigenomics"},{"key":"760_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.10.021","author":"D Cai","year":"2025","unstructured":"Cai D, Li Y, Sun D, et al. Anthocyanin-mediated epigenetic modifications: a new perspective in health promoting and disease prevention. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.10.021.","journal-title":"J Adv Res"},{"issue":"1","key":"760_CR216","doi-asserted-by":"publisher","first-page":"2508426","DOI":"10.1080\/19490976.2025.2508426","volume":"17","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Liu Y, Li Y, et al. Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases. Gut Microbes. 2025;17(1):2508426.","journal-title":"Gut Microbes"},{"key":"760_CR217","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.mce.2015.02.020","volume":"406","author":"S Sinha","year":"2015","unstructured":"Sinha S, Shukla S, Khan S, et al. Epigenetic reactivation of p21CIP1\/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ER\u03b1-dependent in ER\u03b1-negative human breast cancer cells. Mol Cell Endocrinol. 2015;406:102\u201314.","journal-title":"Mol Cell Endocrinol"},{"key":"760_CR218","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1476-4598-12-9","volume":"12","author":"Y Li","year":"2013","unstructured":"Li Y, Meeran SM, Patel SN, et al. Epigenetic reactivation of estrogen receptor-\u03b1 (ER\u03b1) by genistein enhances hormonal therapy sensitivity in ER\u03b1-negative breast cancer. Mol Cancer. 2013;12:9.","journal-title":"Mol Cancer"},{"issue":"1","key":"760_CR219","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s42255-024-01191-9","volume":"7","author":"M Nshanian","year":"2025","unstructured":"Nshanian M, Gruber JJ, Geller BS, et al. Short-chain fatty acid metabolites propionate and butyrate are unique epigenetic regulatory elements linking diet, metabolism and gene expression. Nat Metab. 2025;7(1):196\u2013211.","journal-title":"Nat Metab"},{"issue":"5","key":"760_CR220","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1208\/s12248-019-0355-5","volume":"21","author":"HD Kuo","year":"2019","unstructured":"Kuo HD, Wu R, Li S, et al. Anthocyanin delphinidin prevents neoplastic transformation of mouse skin JB6 P+ cells: epigenetic re-activation of Nrf2-ARE pathway. Aaps j. 2019;21(5):83.","journal-title":"Aaps j"},{"key":"760_CR221","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jff.2018.03.013","volume":"44","author":"AJ Le\u00f3n-Gonz\u00e1lez","year":"2018","unstructured":"Le\u00f3n-Gonz\u00e1lez AJ, Sharif T, Auger C, et al. Anthocyanin-rich bilberry extract induces apoptosis in acute lymphoblastic leukemia cells via redox-sensitive epigenetic modifications. J Funct Foods. 2018;44:227\u201334.","journal-title":"J Funct Foods"},{"issue":"1\u20132","key":"760_CR222","first-page":"80","volume":"593","author":"IP Pogribny","year":"2006","unstructured":"Pogribny IP, Ross SA, Wise C, et al. Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat Res. 2006;593(1\u20132):80\u20137.","journal-title":"Mutat Res"},{"issue":"3","key":"760_CR223","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.stem.2015.01.016","volume":"16","author":"T Chen","year":"2015","unstructured":"Chen T, Hao YJ, Zhang Y, et al. m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. 2015;16(3):289\u2013301.","journal-title":"Cell Stem Cell"},{"issue":"14","key":"760_CR224","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3748\/wjg.v27.i14.1435","volume":"27","author":"M Matboli","year":"2021","unstructured":"Matboli M, Hasanin AH, Hussein R, et al. Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion, in vivo study. World J Gastroenterol. 2021;27(14):1435\u201350.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"760_CR225","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1111\/cas.14133","volume":"110","author":"B Han","year":"2019","unstructured":"Han B, Peng X, Cheng D, et al. Delphinidin suppresses breast carcinogenesis through the HOTAIR\/microRNA-34a axis. Cancer Sci. 2019;110(10):3089\u201397.","journal-title":"Cancer Sci"},{"issue":"12","key":"760_CR226","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/carcin\/bgt295","volume":"34","author":"N Banerjee","year":"2013","unstructured":"Banerjee N, Kim H, Talcott S, et al. Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126\/VCAM-1 and miR-126\/PI3K\/AKT\/mTOR. Carcinogenesis. 2013;34(12):2814\u201322.","journal-title":"Carcinogenesis"},{"issue":"3","key":"760_CR227","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-10-1260","volume":"17","author":"LS Wang","year":"2011","unstructured":"Wang LS, Arnold M, Huang YW, et al. Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res. 2011;17(3):598\u2013610.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"760_CR228","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","volume":"125","author":"N Daver","year":"2015","unstructured":"Daver N, Cortes J, Ravandi F, et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015;125(21):3236\u201345.","journal-title":"Blood"},{"issue":"10","key":"760_CR229","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"760_CR230","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.celrep.2015.09.022","volume":"13","author":"S Kugel","year":"2015","unstructured":"Kugel S, Feldman JL, Klein MA, et al. Identification of and molecular basis for SIRT6 loss-of-function point mutations in cancer. Cell Rep. 2015;13(3):479\u201388.","journal-title":"Cell Rep"},{"issue":"7577","key":"760_CR231","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353.","journal-title":"Nature"},{"issue":"2","key":"760_CR232","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper MJ, Vaz M, Marrone KA, et al. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17(2):75\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"760_CR233","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/cells12030365","volume":"12","author":"S Keshari","year":"2023","unstructured":"Keshari S, Barrodia P, Singh AK. Epigenetic perspective of immunotherapy for cancers. Cells. 2023;12(3):365.","journal-title":"Cells"},{"issue":"8","key":"760_CR234","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, \u00c1lvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 2020;41(8):676\u201391.","journal-title":"Trends Immunol"},{"issue":"6","key":"760_CR235","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper MJ, Vaz M, Chiappinelli KB, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284-300.e21.","journal-title":"Cell"},{"issue":"1","key":"760_CR236","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-024-02041-8","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Jin H, Li Q, et al. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024;23(1):130.","journal-title":"Mol Cancer"},{"issue":"1","key":"760_CR237","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22(1):91.","journal-title":"Mol Cancer"},{"issue":"2","key":"760_CR238","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, et al. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17(2):91\u2013107.","journal-title":"Nat Rev Clin Oncol"},{"key":"760_CR239","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"issue":"11","key":"760_CR240","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","volume":"20","author":"M Motwani","year":"2019","unstructured":"Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019;20(11):657\u201374.","journal-title":"Nat Rev Genet"},{"key":"760_CR241","doi-asserted-by":"publisher","first-page":"1122352","DOI":"10.3389\/fimmu.2023.1122352","volume":"14","author":"C Jie","year":"2023","unstructured":"Jie C, Li R, Cheng Y, et al. Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. Front Immunol. 2023;14:1122352.","journal-title":"Front Immunol"},{"key":"760_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104298","volume":"362","author":"VM Kho","year":"2021","unstructured":"Kho VM, Mekers VE, Span PN, et al. Radiotherapy and cGAS\/STING signaling: impact on MDSCs in the tumor microenvironment. Cell Immunol. 2021;362:104298.","journal-title":"Cell Immunol"},{"issue":"37","key":"760_CR243","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1038\/sj.onc.1206701","volume":"22","author":"P Dent","year":"2003","unstructured":"Dent P, Yacoub A, Fisher PB, et al. MAPK pathways in radiation responses. Oncogene. 2003;22(37):5885\u201396.","journal-title":"Oncogene"},{"key":"760_CR244","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010102","author":"P Maier","year":"2016","unstructured":"Maier P, Hartmann L, Wenz F, et al. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17010102.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"760_CR245","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1667\/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2","volume":"159","author":"A Yacoub","year":"2003","unstructured":"Yacoub A, McKinstry R, Hinman D, et al. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res. 2003;159(4):439\u201352.","journal-title":"Radiat Res"},{"issue":"4","key":"760_CR246","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41419-021-03558-2","volume":"12","author":"P Wu","year":"2021","unstructured":"Wu P, Fang X, Liu Y, et al. N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway. Cell Death Dis. 2021;12(4):298.","journal-title":"Cell Death Dis"},{"issue":"2","key":"760_CR247","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.yexcr.2017.12.006","volume":"362","author":"L Wang","year":"2018","unstructured":"Wang L, Zhao Y, Xiong Y, et al. K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L\/CUX1 pathway. Exp Cell Res. 2018;362(2):424\u201335.","journal-title":"Exp Cell Res"},{"issue":"5","key":"760_CR248","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/1535-7163.MCT-17-1053","volume":"17","author":"BH Rath","year":"2018","unstructured":"Rath BH, Waung I, Camphausen K, et al. Inhibition of the histone H3K27 demethylase UTX enhances tumor cell radiosensitivity. Mol Cancer Ther. 2018;17(5):1070\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"760_CR249","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.4049\/jimmunol.142.7.2560","volume":"142","author":"TF Tedder","year":"1989","unstructured":"Tedder TF, Klejman G, Schlossman SF, et al. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol. 1989;142(7):2560\u20138.","journal-title":"J Immunol"},{"issue":"7","key":"760_CR250","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.4049\/jimmunol.157.7.2939","volume":"157","author":"J Sz\u00f6ll\u00f3si","year":"1996","unstructured":"Sz\u00f6ll\u00f3si J, Horejs\u00ed V, Bene L, et al. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol. 1996;157(7):2939\u201346.","journal-title":"J Immunol"},{"issue":"27","key":"760_CR251","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.1074\/jbc.M800784200","volume":"283","author":"MJ Polyak","year":"2008","unstructured":"Polyak MJ, Li H, Shariat N, et al. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 2008;283(27):18545\u201352.","journal-title":"J Biol Chem"},{"issue":"4","key":"760_CR252","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","volume":"197","author":"E Schuh","year":"2016","unstructured":"Schuh E, Berer K, Mulazzani M, et al. Features of human CD3+CD20+ T cells. J Immunol. 2016;197(4):1111\u20137.","journal-title":"J Immunol"},{"issue":"6","key":"760_CR253","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506.","journal-title":"Haematologica"},{"issue":"5","key":"760_CR254","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677\u201392.","journal-title":"Cancer Cell"},{"issue":"12","key":"760_CR255","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1038\/s41375-022-01716-9","volume":"36","author":"A Benyoucef","year":"2022","unstructured":"Benyoucef A, Haigh K, Cuddihy A, et al. JAK\/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL. Leukemia. 2022;36(12):2802\u201316.","journal-title":"Leukemia"},{"issue":"14","key":"760_CR256","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/sj.onc.1208376","volume":"24","author":"FA Steiner","year":"2005","unstructured":"Steiner FA, Hong JA, Fischette MR, et al. Sequential 5-Aza 2\u2019-deoxycytidine\/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene. 2005;24(14):2386\u201397.","journal-title":"Oncogene"},{"issue":"7","key":"760_CR257","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/0008-5472.CAN-04-2843","volume":"65","author":"Y Xiong","year":"2005","unstructured":"Xiong Y, Dowdy SC, Podratz KC, et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 2005;65(7):2684\u20139.","journal-title":"Cancer Res"},{"issue":"7","key":"760_CR258","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/cncr.23789","volume":"113","author":"A Raza","year":"2008","unstructured":"Raza A, Mehdi M, Mumtaz M, et al. Combination of 5\u2010azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113(7):1596\u2013604.","journal-title":"Cancer"},{"issue":"9","key":"760_CR259","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075136","volume":"8","author":"H Han","year":"2013","unstructured":"Han H, Yang X, Pandiyan K, et al. Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells. PLoS ONE. 2013;8(9):e75136.","journal-title":"PLoS ONE"},{"issue":"1","key":"760_CR260","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380.","journal-title":"Cell"},{"issue":"10","key":"760_CR261","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630\u201341.","journal-title":"Nat Rev Genet"},{"issue":"12","key":"760_CR262","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1210\/en.2011-1056","volume":"152","author":"GL Gravina","year":"2011","unstructured":"Gravina GL, Marampon F, Piccolella M, et al. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology. 2011;152(12):4550\u201361.","journal-title":"Endocrinology"},{"issue":"1","key":"760_CR263","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16\u201322.","journal-title":"Cancer Res"},{"issue":"6","key":"760_CR264","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1158\/0008-5472.CAN-10-1998","volume":"71","author":"Y Li","year":"2011","unstructured":"Li Y, Alsagabi M, Fan D, et al. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 2011;71(6):2108\u201317.","journal-title":"Cancer Res"},{"issue":"5","key":"760_CR265","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jhep.2021.06.025","volume":"75","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liang N, Yang T, et al. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J Hepatol. 2021;75(5):1142\u201353.","journal-title":"J Hepatol"},{"issue":"26","key":"760_CR266","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202216","volume":"9","author":"Y Wei","year":"2022","unstructured":"Wei Y, Chen Q, Huang S, et al. The interaction between DNMT1 and high\u2010mannose CD133 maintains the slow\u2010cycling state and tumorigenic potential of glioma stem cell. Adv Sci. 2022;9(26):e2202216.","journal-title":"Adv Sci"},{"key":"760_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105071","volume":"160","author":"Y Ma","year":"2020","unstructured":"Ma Y, Chai N, Jiang Q, et al. DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to molecular targeting agents. Pharmacol Res. 2020;160:105071.","journal-title":"Pharmacol Res"},{"issue":"1","key":"760_CR268","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13046-019-1442-2","volume":"38","author":"SC Lai","year":"2019","unstructured":"Lai SC, Su YT, Chi CC, et al. DNMT3b\/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6\/STAT3 regulation. J Exp Clin Cancer Res. 2019;38(1):474.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"760_CR269","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41392-024-01778-4","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhao K, Zhou W, et al. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. Signal Transduct Target Ther. 2024;9(1):65.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"760_CR270","doi-asserted-by":"publisher","first-page":"832","DOI":"10.7150\/ijbs.75963","volume":"19","author":"S Lin","year":"2023","unstructured":"Lin S, Ruan H, Qin L, et al. Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-\u03baB activity via UHRF1\/DNMT1 complex. Int J Biol Sci. 2023;19(3):832\u201351.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"760_CR271","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-023-00386-2","volume":"12","author":"WW Liu","year":"2023","unstructured":"Liu WW, Zhang ZY, Wang F, et al. Emerging roles of m6A RNA modification in cancer therapeutic resistance. Exp Hematol Oncol. 2023;12(1):21.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"760_CR272","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-020-00510-w","volume":"53","author":"X Pan","year":"2021","unstructured":"Pan X, Hong X, Li S, et al. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021;53(1):91\u2013102.","journal-title":"Exp Mol Med"},{"key":"760_CR273","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.75231","volume":"11","author":"E Li","year":"2022","unstructured":"Li E, Xia M, Du Y, et al. METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF\/RAD51 axis. Elife. 2022;11:e75231.","journal-title":"Elife"},{"issue":"1","key":"760_CR274","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22922","volume":"36","author":"S Li","year":"2022","unstructured":"Li S, Jiang F, Chen F, et al. Effect of m6A methyltransferase METTL3 -mediated MALAT1\/E2F1\/AGR2 axis on adriamycin resistance in breast cancer. J Biochem Mol Toxicol. 2022;36(1):e22922.","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"760_CR275","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1080\/21655979.2021.1924544","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Cheng Z, Xu J, et al. Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin. Bioengineered. 2021;12(1):1874\u201389.","journal-title":"Bioengineered"},{"issue":"1","key":"760_CR276","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-019-1128-6","volume":"19","author":"B Tang","year":"2020","unstructured":"Tang B, Yang Y, Kang M, et al. m(6)A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 2020;19(1):3.","journal-title":"Mol Cancer"},{"key":"760_CR277","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696371","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, Ou S, Zhou Y, et al. m(6)A Methyltransferase METTL14-mediated upregulation of cytidine deaminase promoting gemcitabine resistance in pancreatic cancer. Front Oncol. 2021;11:696371.","journal-title":"Front Oncol"},{"issue":"6","key":"760_CR278","doi-asserted-by":"publisher","first-page":"304","DOI":"10.21037\/atm-22-556","volume":"10","author":"X Ye","year":"2022","unstructured":"Ye X, Wang LP, Han C, et al. Increased m(6)A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163\/USP44 axis. Ann Transl Med. 2022;10(6):304.","journal-title":"Ann Transl Med"},{"issue":"1","key":"760_CR279","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13046-021-01934-6","volume":"40","author":"X Liu","year":"2021","unstructured":"Liu X, Su K, Sun X, et al. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt\/\u03b2-catenin pathway. J Exp Clin Cancer Res. 2021;40(1):132.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"760_CR280","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.18632\/oncotarget.23554","volume":"9","author":"Y Nishizawa","year":"2018","unstructured":"Nishizawa Y, Konno M, Asai A, et al. Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer. Oncotarget. 2018;9(7):7476\u201386.","journal-title":"Oncotarget"},{"key":"760_CR281","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2022.01.013","volume":"530","author":"C Huang","year":"2022","unstructured":"Huang C, Zhou S, Zhang C, et al. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Cancer Lett. 2022;530:16\u201328.","journal-title":"Cancer Lett"},{"issue":"1","key":"760_CR282","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13046-021-02137-9","volume":"40","author":"K Li","year":"2021","unstructured":"Li K, Peng ZY, Gao S, et al. M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. J Exp Clin Cancer Res. 2021;40(1):325.","journal-title":"J Exp Clin Cancer Res"},{"key":"760_CR283","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2021.09.015","volume":"522","author":"PY Bhattarai","year":"2021","unstructured":"Bhattarai PY, Kim G, Poudel M, et al. METTL3 induces PLX4032 resistance in melanoma by promoting m(6)A-dependent EGFR translation. Cancer Lett. 2021;522:44\u201356.","journal-title":"Cancer Lett"},{"issue":"14","key":"760_CR284","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/ijbs.45886","volume":"16","author":"N Ding","year":"2020","unstructured":"Ding N, You A, Tian W, et al. Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16(14):2595\u2013611.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"760_CR285","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12943-020-01281-8","volume":"19","author":"J Xu","year":"2020","unstructured":"Xu J, Wan Z, Tang M, et al. N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating \u03b2-catenin signaling. Mol Cancer. 2020;19(1):163.","journal-title":"Mol Cancer"},{"issue":"6","key":"760_CR286","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","volume":"164","author":"J Wang","year":"2023","unstructured":"Wang J, Yu H, Dong W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells\u2019 properties and lenvatinib resistance through WNT\/\u03b2-catenin and hippo signaling pathways. Gastroenterology. 2023;164(6):990\u20131005.","journal-title":"Gastroenterology"},{"issue":"12","key":"760_CR287","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103181","volume":"39","author":"Z Lin","year":"2020","unstructured":"Lin Z, Niu Y, Wan A, et al. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. Embo j. 2020;39(12):e103181.","journal-title":"Embo j"},{"issue":"12","key":"760_CR288","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.7150\/thno.55574","volume":"11","author":"K Sun","year":"2021","unstructured":"Sun K, Du Y, Hou Y, et al. Saikosaponin D exhibits anti-leukemic activity by targeting FTO\/m(6)A signaling. Theranostics. 2021;11(12):5831\u201346.","journal-title":"Theranostics"},{"issue":"4","key":"760_CR289","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41388-018-0459-x","volume":"38","author":"J Sun","year":"2019","unstructured":"Sun J, Cai X, Yung MM, et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene. 2019;38(4):564\u201380.","journal-title":"Oncogene"},{"key":"760_CR290","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.omtn.2019.02.010","volume":"16","author":"X Liu","year":"2019","unstructured":"Liu X, Lu X, Zhen F, et al. LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K\/AKT pathway in NSCLC. Mol Ther Nucleic Acids. 2019;16:155\u201361.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"760_CR291","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-022-00902-6","volume":"7","author":"Y Li","year":"2022","unstructured":"Li Y, Gan Y, Liu J, et al. Downregulation of MEIS1 mediated by ELFN1-AS1\/EZH2\/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7(1):87.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"760_CR292","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13058-022-01520-4","volume":"24","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu J, Ebrahimi B, et al. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance. Breast Cancer Res. 2022;24(1):26.","journal-title":"Breast Cancer Res"},{"issue":"20","key":"760_CR293","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1038\/s41388-021-01799-1","volume":"40","author":"M Zhou","year":"2021","unstructured":"Zhou M, Zhang X, Liu C, et al. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6. Oncogene. 2021;40(20):3564\u201377.","journal-title":"Oncogene"},{"issue":"1","key":"760_CR294","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01037-1","volume":"13","author":"C Dominici","year":"2021","unstructured":"Dominici C, Sgarioto N, Yu Z, et al. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Clin Epigenetics. 2021;13(1):54.","journal-title":"Clin Epigenetics"},{"issue":"3","key":"760_CR295","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","volume":"15","author":"K Marjon","year":"2016","unstructured":"Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis. Cell Rep. 2016;15(3):574\u201387.","journal-title":"Cell Rep"},{"issue":"10","key":"760_CR296","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","volume":"24","author":"PJ Hamard","year":"2018","unstructured":"Hamard PJ, Santiago GE, Liu F, et al. PRMT5 Regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Rep. 2018;24(10):2643\u201357.","journal-title":"Cell Rep"},{"issue":"10","key":"760_CR297","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/cancers11101585","volume":"11","author":"J Verigos","year":"2019","unstructured":"Verigos J, Karakaidos P, Kordias D, et al. The histone demethylase LSD1\/\u039aDM1A mediates chemoresistance in breast cancer via regulation of a stem cell program. Cancers (Basel). 2019;11(10):1585.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"760_CR298","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202050922","volume":"22","author":"LJ Zhao","year":"2021","unstructured":"Zhao LJ, Li YY, Zhang YT, et al. Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. EMBO Rep. 2021;22(8):e50922.","journal-title":"EMBO Rep"},{"issue":"8","key":"760_CR299","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.233","volume":"10","author":"B Hu","year":"2020","unstructured":"Hu B, Xu Y, Li YC, et al. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-\u03baB oncogenic signaling. Clin Transl Med. 2020;10(8):e233.","journal-title":"Clin Transl Med"},{"key":"760_CR300","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2017.03.038","volume":"398","author":"M Huang","year":"2017","unstructured":"Huang M, Chen C, Geng J, et al. Targeting KDM1A attenuates Wnt\/\u03b2-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017;398:12\u201321.","journal-title":"Cancer Lett"},{"issue":"47","key":"760_CR301","doi-asserted-by":"publisher","first-page":"81737","DOI":"10.18632\/oncotarget.19387","volume":"8","author":"L Chen","year":"2017","unstructured":"Chen L, Vasilatos SN, Qin Y, et al. Functional characterization of lysine-specific demethylase 2 (LSD2\/KDM1B) in breast cancer progression. Oncotarget. 2017;8(47):81737\u201353.","journal-title":"Oncotarget"},{"issue":"5","key":"760_CR302","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.prp.2019.02.014","volume":"215","author":"Y Wang","year":"2019","unstructured":"Wang Y, Sun L, Luo Y, et al. Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells. Pathol Res Pract. 2019;215(5):1054\u201360.","journal-title":"Pathol Res Pract"},{"key":"760_CR303","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102443","author":"YK Lee","year":"2019","unstructured":"Lee YK, Lim J, Yoon SY, et al. Promotion of cell death in cisplatin-resistant ovarian cancer cells through KDM1B-DCLRE1B modulation. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20102443.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"760_CR304","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40164-023-00434-x","volume":"12","author":"C Bandini","year":"2023","unstructured":"Bandini C, Mereu E, Paradzik T, et al. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. Exp Hematol Oncol. 2023;12(1):71.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"760_CR305","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41598-017-17913-x","volume":"8","author":"T Boulding","year":"2018","unstructured":"Boulding T, McCuaig RD, Tan A, et al. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Sci Rep. 2018;8(1):73.","journal-title":"Sci Rep"},{"issue":"11","key":"760_CR306","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/carcin\/bgz070","volume":"40","author":"SK Sengodan","year":"2019","unstructured":"Sengodan SK, Hemalatha SK, Nadhan R, et al. \u03b2-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue. Carcinogenesis. 2019;40(11):1415\u201326.","journal-title":"Carcinogenesis"},{"issue":"4","key":"760_CR307","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.bbrc.2020.07.044","volume":"530","author":"G Zheng","year":"2020","unstructured":"Zheng G, Chen W, Li W, et al. E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance. Biochem Biophys Res Commun. 2020;530(4):624\u201331.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"760_CR308","first-page":"950","volume":"12","author":"P Sun","year":"2020","unstructured":"Sun P, Sun L, Cui J, et al. Long noncoding RNA HAS2-AS1 accelerates non-small cell lung cancer chemotherapy resistance by targeting LSD1\/EphB3 pathway. Am J Transl Res. 2020;12(3):950\u20138.","journal-title":"Am J Transl Res"},{"issue":"6","key":"760_CR309","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1002\/hep.32079","volume":"74","author":"L Ma","year":"2021","unstructured":"Ma L, Xu A, Kang L, et al. LSD1-Demethylated LINC01134 confers oxaliplatin resistance through SP1-induced p62 transcription in HCC. Hepatology. 2021;74(6):3213\u201334.","journal-title":"Hepatology"},{"issue":"10","key":"760_CR310","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/cbin.12066","volume":"47","author":"J Fan","year":"2023","unstructured":"Fan J, Li H, Ruan Q, et al. The PRMT5 inhibitor C9 mitigates hypoxia-induced carboplatin resistance in lung cancer by inducing autophagy. Cell Biol Int. 2023;47(10):1702\u201315.","journal-title":"Cell Biol Int"},{"issue":"1","key":"760_CR311","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-019-03274-0","volume":"145","author":"B Holmes","year":"2019","unstructured":"Holmes B, Benavides-Serrato A, Saunders JT, et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. J Neurooncol. 2019;145(1):11\u201322.","journal-title":"J Neurooncol"},{"issue":"1","key":"760_CR312","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8(1):69.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"760_CR313","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijrobp.2023.03.067","volume":"117","author":"R Wen","year":"2023","unstructured":"Wen R, Zhou L, Jiang S, et al. DSTN hypomethylation promotes radiotherapy resistance of rectal cancer by activating the Wnt\/\u03b2-catenin signaling pathway. Int J Radiat Oncol Biol Phys. 2023;117(1):198\u2013210.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"760_CR314","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1535-7163.MCT-14-0317","volume":"13","author":"S Wang","year":"2014","unstructured":"Wang S, Zhang R, Claret FX, et al. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther. 2014;13(12):3163\u201374.","journal-title":"Mol Cancer Ther"},{"key":"760_CR315","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112956","author":"S Camero","year":"2021","unstructured":"Camero S, Vitali G, Pontecorvi P, et al. DNMT3A and DNMT3B targeting as an effective radiosensitizing strategy in embryonal rhabdomyosarcoma. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10112956.","journal-title":"Cells"},{"key":"760_CR316","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.omto.2020.04.007","volume":"17","author":"C Wu","year":"2020","unstructured":"Wu C, Guo E, Ming J, et al. Radiation-induced DNMT3B promotes radioresistance in nasopharyngeal carcinoma through methylation of p53 and p21. Mol Ther Oncolytics. 2020;17:306\u201319.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"760_CR317","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jrr\/rraa052","volume":"61","author":"G Zhai","year":"2020","unstructured":"Zhai G, Li J, Zheng J, et al. hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance. J Radiat Res. 2020;61(5):674\u201383.","journal-title":"J Radiat Res"},{"issue":"2","key":"760_CR318","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/ijmr.IJMR_1939_16","volume":"147","author":"S Sood","year":"2018","unstructured":"Sood S, Patel FD, Srinivasan R, et al. Chemoradiation therapy induces in vivo changes in gene promoter methylation & gene transcript expression in patients with invasive cervical cancer. Indian J Med Res. 2018;147(2):151\u20137.","journal-title":"Indian J Med Res"},{"issue":"4","key":"760_CR319","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/onc.2017.351","volume":"37","author":"A Visvanathan","year":"2018","unstructured":"Visvanathan A, Patil V, Arora A, et al. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37(4):522\u201333.","journal-title":"Oncogene"},{"issue":"2","key":"760_CR320","first-page":"621","volume":"52","author":"K Taketo","year":"2018","unstructured":"Taketo K, Konno M, Asai A, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52(2):621\u20139.","journal-title":"Int J Oncol"},{"issue":"3","key":"760_CR321","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molcel.2020.06.017","volume":"79","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen L, Peng D, et al. METTL3 and N6-methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation. Mol Cell. 2020;79(3):425-42.e7.","journal-title":"Mol Cell"},{"issue":"1","key":"760_CR322","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/s41467-020-16722-7","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen H, Yang H, Zhu X, et al. m(5)C modification of mRNA serves a DNA damage code to promote homologous recombination. Nat Commun. 2020;11(1):2834.","journal-title":"Nat Commun"},{"issue":"12","key":"760_CR323","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116251119","volume":"119","author":"H Yang","year":"2022","unstructured":"Yang H, Wang Y, Xiang Y, et al. FMRP promotes transcription-coupled homologous recombination via facilitating TET1-mediated m5C RNA modification demethylation. Proc Natl Acad Sci U S A. 2022;119(12):e2116251119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"760_CR324","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010040","author":"A Kowalski-Chauvel","year":"2020","unstructured":"Kowalski-Chauvel A, Lacore MG, Arnauduc F, et al. The m6A RNA demethylase ALKBH5 promotes radioresistance and invasion capability of glioma stem cells. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers13010040.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"760_CR325","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/mc.22782","volume":"57","author":"S Zhou","year":"2018","unstructured":"Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting \u03b2-catenin through mRNA demethylation. Mol Carcinog. 2018;57(5):590\u20137.","journal-title":"Mol Carcinog"},{"key":"760_CR326","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3389\/fonc.2020.01166","volume":"10","author":"JJ He","year":"2020","unstructured":"He JJ, Li Z, Rong ZX, et al. m(6)A Reader YTHDC2 promotes radiotherapy resistance of nasopharyngeal carcinoma via activating IGF1R\/AKT\/S6 signaling axis. Front Oncol. 2020;10:1166.","journal-title":"Front Oncol"},{"issue":"5","key":"760_CR327","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.21873\/anticanres.14224","volume":"40","author":"TG Lee","year":"2020","unstructured":"Lee TG, Kim SY, Kim HR, et al. Radiation induces autophagy via histone H4 Lysine 20 trimethylation in non-small cell lung cancer cells. Anticancer Res. 2020;40(5):2537\u201348.","journal-title":"Anticancer Res"},{"issue":"9","key":"760_CR328","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1158\/0008-5472.CAN-15-2116","volume":"76","author":"C Peitzsch","year":"2016","unstructured":"Peitzsch C, Cojoc M, Hein L, et al. An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells. Cancer Res. 2016;76(9):2637\u201351.","journal-title":"Cancer Res"},{"issue":"4","key":"760_CR329","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41419-020-2405-4","volume":"11","author":"L Fan","year":"2020","unstructured":"Fan L, Xu S, Zhang F, et al. Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death Dis. 2020;11(4):214.","journal-title":"Cell Death Dis"},{"issue":"1\u20132","key":"760_CR330","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11010-018-3345-5","volume":"449","author":"WW Deng","year":"2018","unstructured":"Deng WW, Hu Q, Liu ZR, et al. KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells. Mol Cell Biochem. 2018;449(1\u20132):81\u201390.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"760_CR331","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","volume":"40","author":"AA Emran","year":"2019","unstructured":"Emran AA, Chatterjee A, Rodger EJ, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019;40(4):328\u201344.","journal-title":"Trends Immunol"},{"issue":"1","key":"760_CR332","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-024-00515-5","volume":"13","author":"R Wang","year":"2024","unstructured":"Wang R, He S, Long J, et al. Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1\/PD-L1 and regulatory pathways. Exp Hematol Oncol. 2024;13(1):46.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"760_CR333","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01398-4","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang T, She Y, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20(1):105.","journal-title":"Mol Cancer"},{"issue":"9","key":"760_CR334","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z Ni","year":"2022","unstructured":"Ni Z, Sun P, Zheng J, et al. JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82(9):1789\u2013802.","journal-title":"Cancer Res"},{"issue":"20","key":"760_CR335","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104514","volume":"39","author":"L Wang","year":"2020","unstructured":"Wang L, Hui H, Agrawal K, et al. m6 A RNA methyltransferases METTL3\/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020;39(20):e104514.","journal-title":"EMBO J"},{"issue":"33","key":"760_CR336","doi-asserted-by":"publisher","first-page":"20159","DOI":"10.1073\/pnas.1918986117","volume":"117","author":"N Li","year":"2020","unstructured":"Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020;117(33):20159\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"760_CR337","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10669-0","volume":"10","author":"S Yang","year":"2019","unstructured":"Yang S, Wei J, Cui YH, et al. m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(1):2782.","journal-title":"Nat Commun"},{"key":"760_CR338","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116048","volume":"221","author":"Y Gao","year":"2024","unstructured":"Gao Y, Feng C, Ma J, et al. Protein arginine methyltransferases (PRMTs): orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance. Biochem Pharmacol. 2024;221:116048.","journal-title":"Biochem Pharmacol"},{"key":"760_CR339","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006890","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li R, Hou N, et al. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-006890.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"760_CR340","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3892\/ol.2015.3337","volume":"10","author":"YL Lin","year":"2015","unstructured":"Lin YL, Gui SL, Ma JG. Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer. Oncol Lett. 2015;10(2):647\u201352.","journal-title":"Oncol Lett"},{"issue":"1","key":"760_CR341","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","volume":"60","author":"M Agundez","year":"2011","unstructured":"Agundez M, Grau L, Palou J, et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Gu\u00e9rin response in patients with T1G3 high-risk bladder tumours. Eur Urol. 2011;60(1):131\u201340.","journal-title":"Eur Urol"},{"issue":"2","key":"760_CR342","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clgc.2011.12.003","volume":"10","author":"JS Kim","year":"2012","unstructured":"Kim JS, Chae Y, Ha YS, et al. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Clin Genitourin Cancer. 2012;10(2):114\u201320.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"760_CR343","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0068-7","volume":"33","author":"YL Lin","year":"2014","unstructured":"Lin YL, Wang YL, Ma JG, et al. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res. 2014;33(1):68.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"760_CR344","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.eururo.2012.05.050","volume":"63","author":"M Alvarez-M\u00fagica","year":"2013","unstructured":"Alvarez-M\u00fagica M, Fern\u00e1ndez-G\u00f3mez JM, Cebrian V, et al. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Gu\u00e9rin response in patients with high-grade non-muscle-invasive bladder carcinoma. Eur Urol. 2013;63(2):364\u201370.","journal-title":"Eur Urol"},{"key":"760_CR345","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/402963","volume":"2015","author":"YW Kim","year":"2015","unstructured":"Kim YW, Yoon HY, Seo SP, et al. Clinical implications and prognostic values of prostate cancer susceptibility candidate methylation in primary nonmuscle invasive bladder cancer. Dis Markers. 2015;2015:402963.","journal-title":"Dis Markers"},{"issue":"4","key":"760_CR346","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.22087","volume":"105","author":"C Yan","year":"2012","unstructured":"Yan C, Kim YW, Ha YS, et al. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer. J Surg Oncol. 2012;105(4):425\u201330.","journal-title":"J Surg Oncol"},{"issue":"16","key":"760_CR347","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1158\/0008-5472.CAN-05-0267","volume":"65","author":"CJ Marsit","year":"2005","unstructured":"Marsit CJ, Karagas MR, Andrew A, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005;65(16):7081\u20135.","journal-title":"Cancer Res"},{"issue":"4","key":"760_CR348","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.juro.2010.05.085","volume":"184","author":"M Alvarez-M\u00fagica","year":"2010","unstructured":"Alvarez-M\u00fagica M, Cebrian V, Fern\u00e1ndez-G\u00f3mez JM, et al. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol. 2010;184(4):1507\u201313.","journal-title":"J Urol"},{"issue":"1","key":"760_CR349","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-015-3302-x","volume":"150","author":"DD Kong","year":"2015","unstructured":"Kong DD, Yang J, Li L, et al. T-cadherin association with clinicopathological features and prognosis in axillary lymph node-positive breast cancer. Breast Cancer Res Treat. 2015;150(1):119\u201326.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"760_CR350","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10549-013-2774-9","volume":"142","author":"L Wu","year":"2013","unstructured":"Wu L, Wang F, Xu R, et al. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2013;142(3):619\u201327.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"760_CR351","first-page":"10716","volume":"8","author":"Z Zhong","year":"2015","unstructured":"Zhong Z, Shan M, Wang J, et al. HOXD13 methylation status is a prognostic indicator in breast cancer. Int J Clin Exp Pathol. 2015;8(9):10716\u201324.","journal-title":"Int J Clin Exp Pathol"},{"issue":"24","key":"760_CR352","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1038\/sj.onc.1209386","volume":"25","author":"J Veeck","year":"2006","unstructured":"Veeck J, Niederacher D, An H, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 2006;25(24):3479\u201388.","journal-title":"Oncogene"},{"issue":"12","key":"760_CR353","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910638","volume":"11","author":"L Ye","year":"2019","unstructured":"Ye L, Lin C, Wang X, et al. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019;11(12):e10638.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"760_CR354","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1078155221989404","volume":"28","author":"R Jahangiri","year":"2022","unstructured":"Jahangiri R, Mosaffa F, Emami Razavi A, et al. PAX2 promoter methylation and AIB1 overexpression promote tamoxifen resistance in breast carcinoma patients. J Oncol Pharm Pract. 2022;28(2):310\u201325.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"760_CR355","first-page":"2855","volume":"15","author":"J Xu","year":"2018","unstructured":"Xu J, Sun T, Guo X, et al. Estrogen receptor-\u03b1 promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer. Oncol Lett. 2018;15(3):2855\u201362.","journal-title":"Oncol Lett"},{"issue":"4\u20135","key":"760_CR356","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clinbiochem.2009.10.009","volume":"43","author":"G Sharma","year":"2010","unstructured":"Sharma G, Mirza S, Parshad R, et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem. 2010;43(4\u20135):373\u20139.","journal-title":"Clin Biochem"},{"issue":"1","key":"760_CR357","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ol.2021.13153","volume":"23","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang F, Zhang F, et al. Correlation between promoter methylation of the LDH-C4 gene and DNMT expression in breast cancer and their prognostic significance. Oncol Lett. 2022;23(1):35.","journal-title":"Oncol Lett"},{"issue":"54","key":"760_CR358","doi-asserted-by":"publisher","first-page":"92483","DOI":"10.18632\/oncotarget.21426","volume":"8","author":"T Benezeder","year":"2017","unstructured":"Benezeder T, Tiran V, Treitler AAN, et al. Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients. Oncotarget. 2017;8(54):92483\u201396.","journal-title":"Oncotarget"},{"issue":"1","key":"760_CR359","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13148-022-01363-y","volume":"14","author":"M Zhou","year":"2022","unstructured":"Zhou M, Yan JQ, Chen QX, et al. Association of H3K9me3 with breast cancer prognosis by estrogen receptor status. Clin Epigenetics. 2022;14(1):135.","journal-title":"Clin Epigenetics"},{"issue":"2","key":"760_CR360","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ijc.11706","volume":"109","author":"A Widschwendter","year":"2004","unstructured":"Widschwendter A, Ivarsson L, Blassnig A, et al. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer. 2004;109(2):163\u20136.","journal-title":"Int J Cancer"},{"issue":"14","key":"760_CR361","doi-asserted-by":"publisher","first-page":"868","DOI":"10.21037\/atm-19-4577","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu J, Nie S, Li S, et al. Methylation-driven genes and their prognostic value in cervical squamous cell carcinoma. Ann Transl Med. 2020;8(14):868.","journal-title":"Ann Transl Med"},{"issue":"1","key":"760_CR362","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13148-023-01538-1","volume":"15","author":"X Li","year":"2023","unstructured":"Li X, Liu H, Zhou X, et al. PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer. Clin Epigenetics. 2023;15(1):123.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"760_CR363","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/mc.20837","volume":"51","author":"S Mitra","year":"2012","unstructured":"Mitra S, Mazumder Indra D, Basu PS, et al. Alterations of RASSF1A in premalignant cervical lesions: clinical and prognostic significance. Mol Carcinog. 2012;51(9):723\u201333.","journal-title":"Mol Carcinog"},{"issue":"8","key":"760_CR364","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/modpathol.2013.32","volume":"26","author":"D Guerrero-Setas","year":"2013","unstructured":"Guerrero-Setas D, P\u00e9rez-Janices N, Blanco-Fernandez L, et al. RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer. Mod Pathol. 2013;26(8):1111\u201322.","journal-title":"Mod Pathol"},{"key":"760_CR365","doi-asserted-by":"publisher","first-page":"3981529","DOI":"10.1155\/2020\/3981529","volume":"2020","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Zhang X, Zhao X, et al. SOX1 and PAX1 are hypermethylated in cervical adenocarcinoma and associated with better prognosis. Biomed Res Int. 2020;2020:3981529.","journal-title":"Biomed Res Int"},{"issue":"5\u20136","key":"760_CR366","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000362738","volume":"86","author":"MK Lee","year":"2014","unstructured":"Lee MK, Jeong EM, Kim JH, et al. Aberrant methylation of the VIM promoter in uterine cervical squamous cell carcinoma. Oncology. 2014;86(5\u20136):359\u201368.","journal-title":"Oncology"},{"issue":"14","key":"760_CR367","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.06.15","volume":"7","author":"NY Wu","year":"2019","unstructured":"Wu NY, Zhang X, Chu T, et al. High methylation of ZNF582 in cervical adenocarcinoma affects radiosensitivity and prognosis. Ann Transl Med. 2019;7(14):328.","journal-title":"Ann Transl Med"},{"issue":"1","key":"760_CR368","first-page":"19","volume":"9","author":"X Lin","year":"2022","unstructured":"Lin X, Wang F, Chen J, et al. N(6)-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil Med Res. 2022;9(1):19.","journal-title":"Mil Med Res"},{"key":"760_CR369","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030477","author":"S Beyer","year":"2017","unstructured":"Beyer S, Zhu J, Mayr D, et al. Histone H3 acetyl K9 and histone H3 tri methyl K4 as prognostic markers for patients with cervical cancer. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18030477.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"760_CR370","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/1878-0261.13178","volume":"16","author":"EL Symonds","year":"2022","unstructured":"Symonds EL, Pedersen SK, Yeo B, et al. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1\/IKZF1. Mol Oncol. 2022;16(10):2031\u201341.","journal-title":"Mol Oncol"},{"issue":"10","key":"760_CR371","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/ijc.27505","volume":"131","author":"AB Philipp","year":"2012","unstructured":"Philipp AB, Stieber P, Nagel D, et al. Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer. 2012;131(10):2308\u201319.","journal-title":"Int J Cancer"},{"issue":"23","key":"760_CR372","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/jnci\/djn359","volume":"100","author":"S Ogino","year":"2008","unstructured":"Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100(23):1734\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"760_CR373","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/07357907.2013.861476","volume":"32","author":"W Jiang","year":"2014","unstructured":"Jiang W, Wang PG, Zhan Y, et al. Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis. Cancer Invest. 2014;32(2):43\u201352.","journal-title":"Cancer Invest"},{"issue":"8","key":"760_CR374","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153009","volume":"216","author":"F Hu","year":"2020","unstructured":"Hu F, Chen L, Bi MY, et al. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: meta-analysis and TCGA analysis. Pathol Res Pract. 2020;216(8):153009.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"760_CR375","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1186\/s12885-019-6436-0","volume":"19","author":"X Liu","year":"2019","unstructured":"Liu X, Fu J, Bi H, et al. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients. BMC Cancer. 2019;19(1):1212.","journal-title":"BMC Cancer"},{"issue":"Suppl 3","key":"760_CR376","doi-asserted-by":"publisher","first-page":"S1481","DOI":"10.1245\/s10434-015-4593-1","volume":"22","author":"MH Tsai","year":"2015","unstructured":"Tsai MH, Chen WC, Yu SL, et al. DNA Hypermethylation of SHISA3 in colorectal cancer: an independent predictor of poor prognosis. Ann Surg Oncol. 2015;22(Suppl 3):S1481\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"760_CR377","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000362820","volume":"88","author":"SJ Park","year":"2015","unstructured":"Park SJ, Kim SM, Hong YS, et al. TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer. Oncology. 2015;88(2):122\u201332.","journal-title":"Oncology"},{"key":"760_CR378","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/1471-2407-14-511","volume":"14","author":"JA Oliver","year":"2014","unstructured":"Oliver JA, Ortiz R, Melguizo C, et al. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer. 2014;14:511.","journal-title":"BMC Cancer"},{"issue":"1","key":"760_CR379","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yexmp.2017.01.006","volume":"102","author":"AB Kassem","year":"2017","unstructured":"Kassem AB, Salem SE, Abdelrahim ME, et al. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. Exp Mol Pathol. 2017;102(1):78\u201385.","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"760_CR380","first-page":"143","volume":"11","author":"A Sood","year":"2012","unstructured":"Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer. 2012;11(2):143\u201350.","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"760_CR381","first-page":"637","volume":"27","author":"H Tamagawa","year":"2012","unstructured":"Tamagawa H, Oshima T, Shiozawa M, et al. The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep. 2012;27(3):637\u201342.","journal-title":"Oncol Rep"},{"issue":"7","key":"760_CR382","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/ijc.24896","volume":"126","author":"L Buckingham","year":"2010","unstructured":"Buckingham L, Penfield Faber L, Kim A, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010;126(7):1630\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"760_CR383","first-page":"113","volume":"33","author":"M Suzuki","year":"2008","unstructured":"Suzuki M, Mohamed S, Nakajima T, et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol. 2008;33(1):113\u20139.","journal-title":"Int J Oncol"},{"issue":"9","key":"760_CR384","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/1878-0261.12848","volume":"15","author":"S Mastoraki","year":"2021","unstructured":"Mastoraki S, Balgkouranidou I, Tsaroucha E, et al. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. Mol Oncol. 2021;15(9):2412\u201322.","journal-title":"Mol Oncol"},{"issue":"9","key":"760_CR385","first-page":"11560","volume":"8","author":"C Chen","year":"2015","unstructured":"Chen C, Hua H, Han C, et al. Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis. Int J Clin Exp Pathol. 2015;8(9):11560\u20134.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"760_CR386","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.bbrc.2015.01.124","volume":"458","author":"C Zhou","year":"2015","unstructured":"Zhou C, Qin Y, Xie Z, et al. NPTX1 is a novel epigenetic regulation gene and associated with prognosis in lung cancer. Biochem Biophys Res Commun. 2015;458(2):381\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"760_CR387","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/cncr.23694","volume":"113","author":"L Tian","year":"2008","unstructured":"Tian L, Suzuki M, Nakajima T, et al. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. Cancer. 2008;113(6):1396\u2013403.","journal-title":"Cancer"},{"issue":"1","key":"760_CR388","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lungcan.2011.09.005","volume":"76","author":"D Wu","year":"2012","unstructured":"Wu D, Xiong L, Wu S, et al. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;76(1):106\u201311.","journal-title":"Lung Cancer"},{"issue":"2","key":"760_CR389","first-page":"161","volume":"42","author":"Y Seok","year":"2019","unstructured":"Seok Y, Lee WK, Park JY, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients. Mol Cells. 2019;42(2):161\u20135.","journal-title":"Mol Cells"},{"issue":"1","key":"760_CR390","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.cllc.2016.06.005","volume":"18","author":"YH Kim","year":"2017","unstructured":"Kim YH, Lee WK, Lee EB, et al. Combined effect of metastasis-related MicroRNA, miR-34 and miR-124 family, methylation on prognosis of non-small-cell lung cancer. Clin Lung Cancer. 2017;18(1):e13\u201320.","journal-title":"Clin Lung Cancer"},{"key":"760_CR391","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2022.152045","volume":"61","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zheng B, Lou K, et al. Methylation patterns of Lys9 and Lys27 on histone H3 correlate with patient outcome and tumor progression in lung cancer. Ann Diagn Pathol. 2022;61:152045.","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"760_CR392","doi-asserted-by":"publisher","first-page":"101042831769223","DOI":"10.1177\/1010428317692230","volume":"39","author":"X Chen","year":"2017","unstructured":"Chen X, Hu H, Liu J, et al. FOXF2 promoter methylation is associated with prognosis in esophageal squamous cell carcinoma. Tumour Biol. 2017;39(2):1010428317692230.","journal-title":"Tumour Biol"},{"issue":"5","key":"760_CR393","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1007\/s13277-015-4489-5","volume":"37","author":"P Ye","year":"2016","unstructured":"Ye P, Qu CF, Hu XL. Impact of IGF-1, IGF-1R, and IGFBP-3 promoter methylation on the risk and prognosis of esophageal carcinoma. Tumour Biol. 2016;37(5):6893\u2013904.","journal-title":"Tumour Biol"},{"issue":"1","key":"760_CR394","doi-asserted-by":"publisher","first-page":"10337","DOI":"10.1038\/s41598-022-14658-0","volume":"12","author":"A Poosari","year":"2022","unstructured":"Poosari A, Nutravong T, Namwat W, et al. The relationship between P16(INK4A) and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand. Sci Rep. 2022;12(1):10337.","journal-title":"Sci Rep"},{"issue":"1","key":"760_CR395","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/07357907.2010.512603","volume":"29","author":"TZ Yi","year":"2011","unstructured":"Yi TZ, Guo J, Zhou L, et al. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Invest. 2011;29(1):86\u201392.","journal-title":"Cancer Invest"},{"issue":"4","key":"760_CR396","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3727\/000000006783981125","volume":"16","author":"H Jo","year":"2006","unstructured":"Jo H, Kim JW, Kang GH, et al. Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res. 2006;16(4):205\u20139.","journal-title":"Oncol Res"},{"issue":"4","key":"760_CR397","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023788","volume":"100","author":"Y Qu","year":"2021","unstructured":"Qu Y, Gao N, Wu T. Expression and clinical significance of SYNE1 and MAGI2 gene promoter methylation in gastric cancer. Medicine (Baltimore). 2021;100(4):e23788.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"760_CR398","first-page":"14228","volume":"8","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dai WJ, Yang XZ. Methylation status of TRAF2 is associated with the diagnosis and prognosis of gastric cancer. Int J Clin Exp Pathol. 2015;8(11):14228\u201334.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"760_CR399","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-011-1070-5","volume":"138","author":"A Di Vinci","year":"2012","unstructured":"Di Vinci A, Casciano I, Marasco E, et al. Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol. 2012;138(1):35\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"760_CR400","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.arcmed.2013.04.004","volume":"44","author":"Y Chen","year":"2013","unstructured":"Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis. Arch Med Res. 2013;44(4):281\u201390.","journal-title":"Arch Med Res"},{"issue":"25","key":"760_CR401","doi-asserted-by":"publisher","first-page":"41011","DOI":"10.18632\/oncotarget.17354","volume":"8","author":"D Goltz","year":"2017","unstructured":"Goltz D, Gevensleben H, Dietrich J, et al. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget. 2017;8(25):41011\u201320.","journal-title":"Oncotarget"},{"issue":"9","key":"760_CR402","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/clinchem\/hvad084","volume":"69","author":"D Dietrich","year":"2023","unstructured":"Dietrich D, Weider S, de Vos L, et al. Circulating cell-free SEPT9 DNA methylation in blood is a biomarker for minimal residual disease detection in head and neck squamous cell carcinoma patients. Clin Chem. 2023;69(9):1050\u201361.","journal-title":"Clin Chem"},{"issue":"17","key":"760_CR403","doi-asserted-by":"publisher","first-page":"28621","DOI":"10.18632\/oncotarget.16157","volume":"8","author":"BG Jiang","year":"2017","unstructured":"Jiang BG, Wang N, Huang J, et al. Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients. Oncotarget. 2017;8(17):28621\u20137.","journal-title":"Oncotarget"},{"issue":"2","key":"760_CR404","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jgh.13154","volume":"31","author":"FK Sun","year":"2016","unstructured":"Sun FK, Sun Q, Fan YC, et al. Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy. J Gastroenterol Hepatol. 2016;31(2):484\u201392.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"760_CR405","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1532\/IJH97.06087","volume":"84","author":"J Hiraga","year":"2006","unstructured":"Hiraga J, Kinoshita T, Ohno T, et al. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol. 2006;84(3):248\u201355.","journal-title":"Int J Hematol"},{"issue":"1","key":"760_CR406","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3810-7","volume":"17","author":"W Huang","year":"2017","unstructured":"Huang W, Xue X, Shan L, et al. Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma. BMC Cancer. 2017;17(1):815.","journal-title":"BMC Cancer"},{"issue":"2","key":"760_CR407","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3892\/ol.2017.6431","volume":"14","author":"W Zhang","year":"2017","unstructured":"Zhang W, Li X, Song G, et al. Prognostic significance of LKB1 promoter methylation in cutaneous malignant melanoma. Oncol Lett. 2017;14(2):2075\u201380.","journal-title":"Oncol Lett"},{"issue":"5","key":"760_CR408","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jid.2016.01.024","volume":"136","author":"MR Roh","year":"2016","unstructured":"Roh MR, Gupta S, Park KH, et al. Promoter methylation of PTEN is a significant prognostic factor in melanoma survival. J Invest Dermatol. 2016;136(5):1002\u201311.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"760_CR409","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4161\/epi.24947","volume":"8","author":"S Martinelli","year":"2013","unstructured":"Martinelli S, Kanduri M, Maffei R, et al. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. Epigenetics. 2013;8(7):720\u20139.","journal-title":"Epigenetics"},{"issue":"2","key":"760_CR410","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.29","volume":"10","author":"TJ Zhang","year":"2020","unstructured":"Zhang TJ, Xu ZJ, Gu Y, et al. Identification and validation of prognosis-related DLX5 methylation as an epigenetic driver in myeloid neoplasms. Clin Transl Med. 2020;10(2):e29.","journal-title":"Clin Transl Med"},{"issue":"6","key":"760_CR411","doi-asserted-by":"publisher","first-page":"9438","DOI":"10.1002\/jcp.27629","volume":"234","author":"XY Lian","year":"2019","unstructured":"Lian XY, Ma JC, Zhou JD, et al. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia. J Cell Physiol. 2019;234(6):9438\u201346.","journal-title":"J Cell Physiol"},{"issue":"24","key":"760_CR412","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-18-0532","volume":"24","author":"Y Li","year":"2018","unstructured":"Li Y, Yang X, Du X, et al. RAB37 hypermethylation regulates metastasis and resistance to docetaxel-based induction chemotherapy in nasopharyngeal carcinoma. Clin Cancer Res. 2018;24(24):6495\u2013508.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"760_CR413","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13046-018-0881-5","volume":"37","author":"XY Ren","year":"2018","unstructured":"Ren XY, Wen X, Li YQ, et al. TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2018;37(1):227.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"760_CR414","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","volume":"112","author":"RD Kalachand","year":"2020","unstructured":"Kalachand RD, Stordal B, Madden S, et al. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020;112(12):1190\u2013203.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"760_CR415","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1515\/cclm-2013-0736","volume":"52","author":"F Zhou","year":"2014","unstructured":"Zhou F, Tao G, Chen X, et al. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival. Clin Chem Lab Med. 2014;52(5):735\u201342.","journal-title":"Clin Chem Lab Med"},{"key":"760_CR416","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7279243","volume":"2023","author":"J Ye","year":"2023","unstructured":"Ye J, Wu M, He L, et al. Glutathione-S-transferase p1 gene promoter methylation in cell-free DNA as a diagnostic and prognostic tool for prostate cancer: a systematic review and meta-analysis. Int J Endocrinol. 2023;2023:7279243.","journal-title":"Int J Endocrinol"},{"issue":"6","key":"760_CR417","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.juro.2014.06.075","volume":"192","author":"K Daniunaite","year":"2014","unstructured":"Daniunaite K, Jarmalaite S, Kalinauskaite N, et al. Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol. 2014;192(6):1849\u201355.","journal-title":"J Urol"},{"issue":"15","key":"760_CR418","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1158\/1078-0432.CCR-14-2049","volume":"21","author":"IA Deckers","year":"2015","unstructured":"Deckers IA, Schouten LJ, Van Neste L, et al. Promoter methylation of CDO1 identifies clear-cell renal cell cancer patients with poor survival outcome. Clin Cancer Res. 2015;21(15):3492\u2013500.","journal-title":"Clin Cancer Res"},{"key":"760_CR419","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.12659\/MSM.895603","volume":"21","author":"YL Lin","year":"2015","unstructured":"Lin YL, Gui SL, Guo H, et al. Protocadherin17 promoter methylation is a potential predictive biomarker in clear cell renal cell carcinoma. Med Sci Monit. 2015;21:2870\u20136.","journal-title":"Med Sci Monit"},{"issue":"1","key":"760_CR420","first-page":"338","volume":"39","author":"YM Cao","year":"2018","unstructured":"Cao YM, Gu J, Zhang YS, et al. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation. Oncol Rep. 2018;39(1):338\u201348.","journal-title":"Oncol Rep"},{"issue":"46","key":"760_CR421","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008630","volume":"96","author":"H Niu","year":"2017","unstructured":"Niu H, Yang J, Yang K, et al. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA). Medicine (Baltimore). 2017;96(46):e8630.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"760_CR422","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2217\/bmm-2018-0012","volume":"12","author":"L Song","year":"2018","unstructured":"Song L, Guo S, Wang J, et al. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med. 2018;12(9):961\u201373.","journal-title":"Biomark Med"},{"issue":"9","key":"760_CR423","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41416-018-0035-8","volume":"118","author":"J Bergheim","year":"2018","unstructured":"Bergheim J, Semaan A, Gevensleben H, et al. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Br J Cancer. 2018;118(9):1217\u201328.","journal-title":"Br J Cancer"},{"issue":"11","key":"760_CR424","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/gutjnl-2016-313372","volume":"67","author":"L Barault","year":"2018","unstructured":"Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018;67(11):1995\u20132005.","journal-title":"Gut"},{"issue":"7","key":"760_CR425","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/cncr.32695","volume":"126","author":"EL Symonds","year":"2020","unstructured":"Symonds EL, Pedersen SK, Murray D, et al. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer. 2020;126(7):1460\u20139.","journal-title":"Cancer"},{"issue":"11","key":"760_CR426","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nmat4997","volume":"16","author":"RH Xu","year":"2017","unstructured":"Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155\u201361.","journal-title":"Nat Mater"},{"issue":"9","key":"760_CR427","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/annonc\/mdv272","volume":"26","author":"L Barault","year":"2015","unstructured":"Barault L, Amatu A, Bleeker FE, et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015;26(9):1994\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"760_CR428","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13073-017-0499-9","volume":"9","author":"M Widschwendter","year":"2017","unstructured":"Widschwendter M, Evans I, Jones A, et al. Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. 2017;9(1):115.","journal-title":"Genome Med"},{"issue":"18","key":"760_CR429","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1038\/s41388-018-0660-y","volume":"38","author":"M Panagopoulou","year":"2019","unstructured":"Panagopoulou M, Karaglani M, Balgkouranidou I, et al. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene. 2019;38(18):3387\u2013401.","journal-title":"Oncogene"},{"key":"760_CR430","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.11.012","volume":"125","author":"M Rusan","year":"2020","unstructured":"Rusan M, Andersen RF, Jakobsen A, et al. Circulating HOXA9-methylated tumour DNA: a novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2020;125:121\u20139.","journal-title":"Eur J Cancer"},{"issue":"10","key":"760_CR431","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141(10):1159\u201368.","journal-title":"Blood"},{"issue":"8002","key":"760_CR432","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, Kuze Y, Kobayashi S, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627(8002):221\u20138.","journal-title":"Nature"},{"issue":"10","key":"760_CR433","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.4103\/1673-5374.392890","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang L, Lyu T, et al. Association of DNA methylation\/demethylation with the functional outcome of stroke in a hyperinflammatory state. Neural Regen Res. 2024;19(10):2229\u201339.","journal-title":"Neural Regen Res"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00760-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00760-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00760-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:02:12Z","timestamp":1771509732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00760-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":433,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00760-w","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors; it does not require the approval of the independent ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}